


Control over Stereogenic N–N Axes by Pd-Catalyzed 5-endo-Hydroaminocyclizations

Valeriia Hutskalova
Christof Sparr*

Department of Chemistry, University of Basel, St. Johans-Ring 19,
4056 Basel, Switzerland
christof.sparr@unibas.ch
http://sparr.chemie.unibas.ch

Dedicated to Prof. Cristina Nevado, recipient of the 2021 Dr. Margaret
Faul Women in Chemistry Award

Published as part of the
Special Issue dedicated to Prof. Cristina Nevado, recipient of the 2021 Dr. Margaret Faul Women in Chemistry Award



Received: 23.09.2022

Accepted after revision: 06.12.2022

Published online: 06.12.2022 (Accepted Manuscript), 16.01.2023 (Version of Record)
DOI: 10.1055/a-1993-6899; Art ID: SS-2022-09-0460-OP

License terms:


© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Abstract A novel approach for the stereoselective construction of N–N atropisomeric compounds by a Pd-catalyzed 5-endo-hydroaminocyclization is described herein. A broad range of bisheterocycles, connected by a configurationally stable N–N stereogenic axis, were prepared with catalyst control in enantioenriched form.

Key words palladium, cyclization, heterocycles, asymmetric catalysis, alkynes, atropisomers

Atropisomers, which arise from the restricted rotation about a single bond, have distinctly defined topologies and are frequently encountered in drug development campaigns.¹ Substituted biaryls possessing a C–C stereogenic axis are one of the most extensively explored and developed classes of atropisomers and they have found diverse applications, for instance as ligands in stereoselective catalysis.^{2–6} In recent years, synthetic efforts have been increasingly devoted to methods for catalyst-controlled stereoselectivity to forge N–C atropisomers.^{7–13} However, in contrast to the well-developed C–C and N–C atropisomers, scaffolds featuring N–N stereogenic axes have remained underexplored, despite an early report of N–N atropisomerism in 1931.¹⁴ Currently, N–N atropisomers are represented by a small number of natural products and bioactive compounds, such as dixiamycins¹⁵ and β -carboline dimers,¹⁶ and they have also found applications as OLED materials¹⁷ and ligands (Scheme 1A).¹⁸ It was only recently that the first reports on the atroposelective synthesis of scaffolds possessing N–N stereogenic axes were disclosed.^{19–24} with rare examples of indole-carbazole scaffolds obtained only with low enantioselectivities.^{24b} Lu, Houk, and co-workers uti-


lized a strategy based on a quinidine-catalyzed *N*-allyl alkylation reaction,¹⁹ while Li and co-workers developed an organocatalytic atroposelective *N*-acylation²⁰ and a stereo-



selective *N*-alkylation via asymmetric phase-transfer catalysis (Scheme 1B).²¹ Desymmetrization via stereoselective metal catalysis was also applied for the atroposelective synthesis of *N*-*N* biaryls by Liu and co-workers,²² and the most recent strategies by Zhao and Shi are based on stereoselective Paal–Knorr reactions.²³ Despite these seminal strategies, efficient procedures to prepare *N*-*N* stereogenic compounds are still scarce. Inspired by the atroposelective synthesis of *N*-*C* atropisomeric indoles by the Kitagawa group,²⁵ we thus considered if the *de novo* construction of indole rings by a catalytic 5-*endo*-hydroaminocyclization²⁶ allows the configuration of *N*-*N* stereogenic axes to be controlled (Scheme 1).

We initiated our studies with an expeditious precursor synthesis from readily available substrates by the formation of an *N*-aminocarbazole with HOSA, a subsequent Buchwald–Hartwig amination, and a Sonogashira coupling yielding **2a** (Scheme 2).


With the alkyne precursor in hand, we performed an extensive optimization to explore the impact of different parameters on the 5-*endo*-hydroaminocyclization (Table 1, see the Supporting Information for details). Initial investi-



Scheme 2 Precursor synthesis, HOSA = hydroxylamine-*O*-sulfonic acid

gations showed that Pd^{II} performs best among all tested transition metals (Au^I, Ag^I, Cu^I) (Table S1 in the Supporting Information) and that the presence of chloride is beneficial. The replacement of chloride by bromide caused a significant drop in atroposelectivity (Table 1, entry 14), while the utilization of Pd(OAc)₂ yielded a racemic product (entry 13).


Table 1 Optimization of the Reaction Conditions for Atroposelective 5-*endo*-Hydroaminocyclization^a



Entry	[Pd]	[Pd] (equiv)	Ligand	Ligand (equiv)	Solvent	Additives/Deviations	Conversion ^b (%)	e.r.
1	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>R</i>)-Monophos	1.2	EtOH	–	100	52:48
2	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>S</i>)-BINAP	1.2	EtOH	–	26	49:51
3	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>R</i>)-Tol-BINAP	1.2	EtOH	–	52	55:45
4	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>S</i>)-SEGPHOS	1.2	EtOH	–	37	35:65
5	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>S</i>)-DIFLUOROPHOS	1.2	EtOH	–	38	33:67
6	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>R</i>)-DTBM-SEGPHOS	1.2	EtOH	–	5	52:48
7	Pd(CH ₃ CN) ₂ Cl ₂	0.60	(<i>R</i>)-DM-SEGPHOS	1.2	EtOH	–	69	83:17
8	Pd(CH ₃ CN) ₂ Cl ₂	0.30	(<i>R</i>)-DM-SEGPHOS	0.60	EtOH	–	66	81:19
9	Pd(CH ₃ CN) ₂ Cl ₂	0.20	(<i>R</i>)-DM-SEGPHOS	0.40	EtOH	–	59	81:19
10	Pd(CH ₃ CN) ₂ Cl ₂	0.20	(<i>R</i>)-DM-SEGPHOS	0.40	EtOH	42 h	100	80:20
11	Pd(CH ₃ CN) ₂ Cl ₂	0.20	(<i>R</i>)-DM-SEGPHOS	0.40	EtOH	argon	47	82:18
12	Pd(CH ₃ CN) ₂ Cl ₂	0.10	(<i>R</i>)-DM-SEGPHOS	0.20	EtOH	–	41	79:21
13	Pd(OAc) ₂	0.30	(<i>R</i>)-DM-SEGPHOS	0.60	EtOH	–	100	50:50
14	Pd(CH ₃ CN) ₄ (BF ₄) ₂	0.30	(<i>R</i>)-DM-SEGPHOS	0.60	EtOH	TBAB (0.70 equiv)	62	56:44
15	Pd(CH ₃ CN) ₄ (BF ₄) ₂	0.30	(<i>R</i>)-DM-SEGPHOS	0.60	EtOH	CsF (0.66 equiv)	0	–
16	Pd(CH ₃ CN) ₂ Cl ₂	0.30	(<i>R</i>)-DM-SEGPHOS	0.60	<i>i</i> PrOH	–	10	83:17

^a Reaction conditions: Pd salt, additive, ligand, solvent (1.5 mL) were stirred for 1 h at r.t. Then **2a** (6.00 μmol) was added and the mixture was stirred at the indicated temperature for 18 h.

^b Conversion and e.r. were determined by NP-HPLC (Chiralpak IG, 3 μm; heptane/*i*PrOH 97.5:2.5; 40 °C; 1 mL/min).



Scheme 3 Substrate scope. Reagents and conditions: **2a-m**, **3a-n** (40.0 μmol , 1.00 equiv), $\text{Pd}(\text{CH}_3\text{CN})_2\text{Cl}_2$ (8.00 μmol , 20 mol%), (*R*)-DM-SEGPHOS (16.0 μmol , 40 mol%), EtOH (10 mL), 80 °C, 66 h; ^a 90 h.

The examination of a wide range of ligands revealed (*R*)-DM-SEGPHOS in EtOH as the best system (entries 1–12). Notably, the application of an aprotic reaction medium or their combination with protic solvents resulted in reaction suppression (Table S3 in the Supporting Information) and the switch from EtOH to *i*PrOH caused a slight increase in atroposelectivity, but with drastically decreased reaction efficiency (entry 16). As a control experiment, separately


prepared and purified $\text{Pd}((R)\text{-DM-SEGPHOS})\text{Cl}_2$ was directly subjected to the 5-*endo*-hydroaminocyclization. The results were comparable as with the *in situ* generated Pd^{II} complex, indicating that the catalyst is efficiently formed prior to the cyclization (Table S3 in the Supporting Information). After establishing the optimal reaction conditions (Table 1, entry 10), we set out to investigate the scope of the developed methodology (Scheme 3). The modularity of the

divergent synthetic strategy was confirmed by dividing the target scaffold into three structural segments. Since altering the steric features and electronic nature of the substituents at all three segments can substantially affect atroposelectivity, we initiated a systematic investigation of each variable. In particular, the alkyne precursors possessing indole moieties showed considerably lower enantioselectivities upon cyclization ((*S_a*)-**5b/5c/6a**) than the carbazole-substituted analogues ((*S_a*)-**5d**).

The examination of the substituents at the 2-position of the carbazole moiety showed that bulky groups lead to higher selectivities. This tendency is further observed for compounds (*S_a*)-**5a-f**, where, for instance, the replacement of the methyl ((*S_a*)-**5d**) with a *tert*-butyl group ((*S_a*)-**5f**) caused an increase of enantioenrichment from 73:27 to 83:17 e.r. However, our method was found to be incompatible with substituents at the 1-position of the carbazole (**5m**). Variations at the alkyne (site B) revealed that the introduction of a *p*-methyl group had a favorable effect on selectivity ((*S_a*)-**5a**/*S_a*)-**6e**, (*S_a*)-**5e**/*S_a*)-**6d**, (*S_a*)-**5f**/*S_a*)-**6b**).

However, a methyl group located at closer proximity to the reaction center ((*S_a*)-**6g**) led to decreased atroposelectivity (77:23 e.r.) and longer reaction times. In contrast, the presence of a methoxy group at the same position resulted in lower enantioselectivity ((*S_a*)-**6k**, (*S_a*)-**6l**), whereas the introduction of two substituents at the *o*-positions of the aromatic ring yielded alkyne precursors that were unreactive under the standard conditions (**6m**, **6n**). To confirm the configurational stability of the synthesized N–N atropisomers, we evaluated the rotational barriers of substrates **5b** and **6d**. While **6d** proved to be configurationally stable at 160 °C after 7 hours ($\Delta G^\ddagger > 140$ kJ·mol⁻¹), a slow racemization of **5b** was observed at 120 °C with a rotational barrier at 129 kJ·mol⁻¹ (see the Supporting Information for details). Finally, modifications of the aniline moiety (site C) were performed (Scheme 4). Substrates possessing F, Cl, Me groups at different positions smoothly underwent the cyclization with almost identical enantioselectivities, indicating that substituents at the modulation site C do not have a strong impact on the reaction outcome. Interestingly, the common side product of the cyclization step was the carbazole arising from N–N bond cleavage. To shed some light on this undesired process, we explored the 2-phenyl-9*H*-carbazole formation for products (*S_a*)-**5a** and (*S_a*)-**6k** (see the Supporting Information).

In particular, control experiments demonstrated that the alkyne precursor is inert towards N–N bond cleavage upon reflux in EtOH and treatment with (*R*)-DM-SEGPHOS (Table S5). The cyclization product (*S_a*)-**5a** also proved to be stable towards Pd^{II} salts, (*R*)-DM-SEGPHOS, and heating, as neither decomposition nor kinetic resolution was detected. These results support the notion that N–N bond cleavage is a Pd-catalyzed process involving the alkyne precursor and competing with the desired cyclization (up to 35% conver-



sion of the alkyne precursor to the side product). Based on the mechanistic proposal by Kitagawa,^{25b} this side reaction for a N–N bond activation could be initiated by coordination of nitrogen to Pd that competes with the formation of the alkyne–Pd complex.

In summary, a concise and practical enantioselective approach to atropisomers possessing an N–N stereogenic axis by a Pd-catalyzed 5-*endo*-hydroaminocyclization was developed. The structural modularity of the method allowed the preparation of a broad range of N–N-linked bisindoles and indolyl-carbazoles with up to 87:13 atroposelectivity and 90% yield.

All reaction solvents and reagents were obtained from commercial suppliers and used without further purification unless otherwise stated. Solvents for extractions and chromatography were technical grade. Syringes were used to transfer air- and moisture-sensitive liquids and solutions. Analytical thin layer chromatography (Merck silica gel 60 F₂₅₄ plates) was utilized for monitoring reactions and visualized by UV light (254 nm and 350 nm). Flash chromatography was performed with SiliCycle silica gel 60 (230–400 mesh) or otherwise stated stationary columns. Concentration *in vacuo* was performed by rotary evaporation to ~10 mbar at 40 °C and drying at ~10⁻² mbar at r.t.

¹H NMR spectra were recorded on Bruker DPX 400 MHz or Bruker DRX 500 MHz spectrometers at 298 K in the indicated deuterated solvent supplied by Cambridge Isotope Laboratories. ¹H NMR spectra are referenced to the residual solvent peak ($\delta = 7.26$ for CDCl₃ and $\delta = 2.50$ for DMSO-*d*₆). ¹³C and 2D NMR spectra were recorded with ¹H-decoupling on Bruker DRX 500 MHz spectrometers at 298 K in the indicated

deuterated solvent supplied by Cambridge Isotope Laboratories. ^{13}C NMR spectra are referenced to the residual solvent peak ($\delta = 77.16$ for CDCl_3 and $\delta = 39.52$ for $\text{DMSO}-d_6$).

Melting points were measured on a Büchi B-565 melting point apparatus and are uncorrected. IR spectroscopy was measured on an ATR Varian Scimitar 800 FT-IR spectrometer. High-resolution mass spectrometry (HRMS-ESI) was recorded by Dr. Michael Pfeffer at the University of Basel on a Bruker Maxis 4G QTOF ESI mass spectrometer. Optical rotations were measured at 296 K on a Jasco P-2000 digital polarimeter with a path length of 10.0 cm, using the 589.3 nm sodium D-line and concentrations are reported in g/100 mL. UV/Vis spectra were measured in MeCN solution on a Jasco V-770 spectrometer with a 10-mm sample cell at 20 °C. Circular dichroism (CD) spectra were acquired in MeCN solution on a Jasco J-1500 CD spectrometer using a 10-mm quartz cuvette at 20 °C.

Synthesis of 5a–5l/6a–6n/7a–7e; General Procedure

$\text{Pd}(\text{CH}_3\text{CN})_2\text{Cl}_2$ (2.08 mg, 8.00 μmol , 20 mol%) and (*R*)-DM-SEGPHOS (11.6 mg, 16.0 μmol , 40 mol%) were transferred to a vial and dry EtOH (5.0 mL) was added. The resulting mixture was stirred for 1 h at r.t. before the corresponding alkyne precursor (**2a–2l**, **3a–3n**, **4a–4e**) (40.0 μmol , 1.00 equiv) and additional dry EtOH (5 mL) were added. The reaction mixture was stirred for 66 h (unless otherwise noted) at 80 °C. The reaction completion was checked by NP-HPLC analysis and then the solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel, cyclohexane/ CH_2Cl_2 from 1:0 to 10:1) or preparative TLC (silica gel) to yield the product.

(*S*_a)-2-Phenyl-9-(2-phenyl-1*H*-indol-1-yl)-9*H*-carbazole ((*S*_a)-5a)

Prepared according to the general procedure using 2-phenyl-*N*-(2-(phenylethynyl)phenyl)-9*H*-carbazol-9-amine (**2a**; 17.4 mg, 40.0 μmol , 1.00 equiv) followed by column chromatography (silica gel) to give (*S*_a)-**5a** (11.0 mg, 25.3 μmol , 63%) as a beige solid; mp 120.7–121.2 °C; $[\alpha]_D^{22} -17.7$ (c 0.6, CHCl_3); $R_f = 0.51$ (cyclohexane/EtOAc 20:1).

IR (neat): 3058w, 3051w, 2961w, 2925w, 2860w, 1731w, 1607m, 1454s, 1334w, 1259m, 1248m, 1076w, 1016m, 908w, 797m, 742s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): $\delta = 8.16$ (d, $^3J = 8.1$ Hz, 1 H, C4'H), 8.13–8.08 (m, 1 H, C5'H), 7.74 (d, $^3J = 7.9$ Hz, 1 H, C4'H), 7.57–7.50 (m, 3 H, C2''H, C6''H, C3'H), 7.44–7.37 (m, 2 H, C2''H, C6''H), 7.38–7.28 (m, 5 H, C6'H, C7'H, C3''H, C5''H, C4''H), 7.24–7.18 (m, 2 H, C1'H, C5H), 7.15–7.10 (m, 3 H, C3''H, C5''H, C4''H), 7.08–7.03 (m, 1 H, C6H), 7.00–6.94 (m, 2 H, C8'H, C3H), 6.68–6.60 (m, 1 H, C7H).

^{13}C NMR (126 MHz, CDCl_3): $\delta = 141.25$ (C1'''), 141.20 (C2), 141.18 (C9a'), 141.0 (C8a'), 140.3 (C2'), 137.8 (C7a), 130.5 (C1''), 128.7 (C3''', C5'''), 128.6 (C3'', C5''), 128.2 (C4''), 127.5 (C2''', C6'''), 127.30 (C4'''), 127.26 (C2'', C6''), 126.70 (C7'), 126.68 (C3a), 123.3 (C6), 121.9 (C5), 121.5 (C4b'), 121.2 (C6'), 121.0 (C4), 120.9 (C4'), 120.7 (C3'), 120.6 (C5'), 109.7 (C7), 109.1 (C8'), 107.3 (C1'), 102.2 (C3).

HRMS (ESI): m/z [M]⁺ calcd for $\text{C}_{32}\text{H}_{22}\text{N}_2$; 434.1778; found: 434.1769.

The e.r. of 80:20 for (*S*_a)-**5a** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): $t_R = 6.60$ (major), 6.97 min (minor).

(*S*_a)-2-Phenyl-1,1'-biindole ((*S*_a)-5b)

Prepared according to the general procedure using *N*-(2-(phenylethynyl)phenyl)-1*H*-indol-1-amine (**2b**; 12.3 mg, 40.0 μmol , 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/ CH_2Cl_2 , 65:35) to give (*S*_a)-**5b** (8.10 mg, 26.3 μmol , 66%) as a viscous yellow solid; $[\alpha]_D^{24} -4.8$ (c 0.4, CHCl_3); $R_f = 0.60$ (cyclohexane/ CH_2Cl_2 65:35).

IR (neat): 3106w, 3057w, 2660w, 2925w, 2853w, 1731w, 1601w, 1488w, 1452s, 1331m, 1272w, 1236w, 1213w, 1179w, 1102w, 1026w, 1009w, 922w, 848w, 800w, 758m, 738 cm^{-1} .

^1H NMR (500 MHz, CDCl_3): $\delta = 7.70$ (d, $^3J = 7.9$ Hz, 1 H, C4H), 7.68–7.66 (m, 1 H, C4'H), 7.29–7.26 (m, 2 H, C2''H, C6''H), 7.23–7.12 (m, 8 H, C5H, C6H, C3''H, C4''H, C5''H, C5'H, C6'H, C2'H), 6.96 (d, $^3J = 7.5$ Hz, 1 H, C7'H), 6.87 (s, 1 H, C3H), 6.77 (d, $^3J = 8.1$ Hz, 1 H, C7H), 6.62 (d, $^3J = 3.2$ Hz, 1 H, C3'H).

^{13}C NMR (126 MHz, CDCl_3): $\delta = 140.5$ (C2), 138.8 (C7a), 136.7 (C7a'), 130.3 (C1''), 128.6 (C3'', C5''), 128.18 (C4''), 128.15 (C2'), 127.2 (C2'', C6''), 126.2 (C3a'), 125.9 (C3a), 123.41 (C6), 123.35 (C6'), 121.8 (C5), 121.4 (C4'), 121.1 (C5'), 120.9 (C4), 109.4 (C7), 109.3 (C7'), 102.5 (C3'), 101.8 (C3).

HRMS (ESI): m/z [M – H]⁻ calcd for $\text{C}_{22}\text{H}_{13}\text{N}_2$; 307.1241; found: 307.1244.

The e.r. of 55:45 for (*S*_a)-**5b** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): $t_R = 5.58$ (major), 6.03 min (minor).

(*S*_a)-2,3-Dimethyl-2'-phenyl-1,1'-biindole ((*S*_a)-5c)

Prepared according to the general procedure using 2,3-dimethyl-*N*-(2-(phenylethynyl)phenyl)-1*H*-indol-1-amine (**2c**; 13.5 mg, 40.0 μmol , 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/ CH_2Cl_2 , 3:1) to give (*S*_a)-**5c** (7.40 mg, 22.0 μmol , 55%) as a beige viscous solid; $[\alpha]_D^{24} +4.4$ (c 0.5, CHCl_3); $R_f = 0.64$ (cyclohexane/ CH_2Cl_2 3:1).

IR (neat): 3053w, 2968w, 2916w, 1729w, 1606w, 1457m, 1410w, 1334w, 1284w, 1230m, 1075m, 907s, 799w, 736s, 695m, 614m cm^{-1} .

^1H NMR (500 MHz, CDCl_3): $\delta = 7.69$ (dt, $^3J = 7.9$, $^4J = 0.7$ Hz, 1 H, C4H), 7.57 (dt, $^3J = 7.6$, $^4J = 1.0$ Hz, 1 H, C4'H), 7.30–7.26 (m, 2 H, C2''H, C6''H), 7.23–7.18 (m, 4 H, C5H, C3''H, C4''H, C5''H), 7.18–7.16 (m, 1 H, C5'H), 7.15–7.11 (m, 1 H, C6'H), 7.11–7.08 (m, 1 H, C6H), 7.00–6.96 (m, 1 H, C7'H), 6.89 (d, $^4J = 0.7$ Hz, 1 H, C3H), 6.65–6.61 (m, 1 H, C7H), 2.27–2.20 (3 H, C3'-CH₃), 1.82 (3 H, C2'-CH₃).

^{13}C NMR (126 MHz, CDCl_3): $\delta = 140.8$ (C2), 138.6 (C7a), 136.7 (C7a'), 133.3 (C2'), 130.8 (C1''), 128.8 (C3'', C5''), 128.2 (C4''), 127.34 (C2'', C6''), 127.26 (C3a'), 126.2 (C3a), 123.4 (C6), 122.4 (C6'), 121.8 (C5), 120.9 (C4), 120.6 (C5'), 118.5 (C4'), 109.6 (C7), 108.9 (C7'), 107.5 (C3'), 101.6 (C3), 9.0 (C3'-CH₃), 8.9 (C2'-CH₃).

HRMS (ESI): m/z [M + H]⁺ calcd for $\text{C}_{24}\text{H}_{21}\text{N}_2$; 337.1699; found: 337.1699.

The e.r. of 64:36 for (*S*_a)-**5c** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): $t_R = 4.33$ (major), 4.67 min (minor).

(*S*_a)-2-Methyl-9-(2-phenyl-1*H*-indol-1-yl)-9*H*-carbazole ((*S*_a)-5d)

Prepared according to the general procedure using 2-methyl-*N*-(2-(phenylethynyl)phenyl)-9*H*-carbazol-9-amine (**2d**; 14.9 mg, 40.0 μmol , 1.00 equiv) followed by column chromatography (silica gel, cyclohexane/EtOAc from 1:0 to 10:1) to give (*S*_a)-**5d** (8.00 mg, 21.5 μmol , 54%) as a brown solid; mp 111.9–113.0 °C; $[\alpha]_D^{24} -0.5$ (c 0.4, CHCl_3); $R_f = 0.65$ (cyclohexane/EtOAc 10:1).

IR (neat): 3056w, 3032w, 2959w, 2920w, 2852w, 1629w, 1605m, 1581w, 1490m, 1452s, 1409w, 1329m, 1285m, 1261w, 1230s, 1179w, 1099w, 1022m, 912w cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.05 (d, 3J = 6.8 Hz, 1 H, C5'H), 7.98 (d, 3J = 7.9 Hz, 1 H, C4'H), 7.74 (d, 3J = 7.7 Hz, 1 H, C4H), 7.43–7.35 (m, 2 H, C2''H, C6''H), 7.32–7.27 (m, 2 H, C6'H, C7'H), 7.20 (t, 3J = 7.3 Hz, 1 H, C5H), 7.16–7.08 (m, 4 H, C3''H, C4''H, C5''H, C3'H), 7.07–7.01 (m, 1 H, C6H), 6.95 (s, 1 H, C3H), 6.93 (d, 3J = 7.3 Hz, 1 H, C8'H), 6.80 (s, 1 H, C1'H), 6.56 (d, 3J = 8.2 Hz, 1 H, C7H), 2.39 (s, 3 H, CH_3).

^{13}C NMR (126 MHz, CDCl_3): δ = 141.24 (C2), 141.21 (C9a'), 140.7 (C8a'), 137.9 (C7a), 137.4 (C2'), 130.7 (C1''), 128.7 (C3'', C5''), 128.3 (C4''), 127.4 (C2'', C6''), 126.8 (C3a), 126.3 (C7'), 123.4 (C6), 122.8 (C3'), 121.9 (C5), 121.1 (C4b'), 121.1 (C6'), 120.41 (C4'), 120.34 (C5'), 119.6 (C4a'), 109.8 (C7), 109.3 (C1'), 109.1 (C8'), 102.1 (C3), 22.2 (CH_3).

HRMS (ESI): m/z [$\text{M} - \text{H}$] $^-$ calcd for $\text{C}_{27}\text{H}_{19}\text{N}_2$: 371.1554; found: 371.1552.

The e.r. of 73:27 for (S_a)-**5d** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min $^{-1}$, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 5.37 (major), 5.13 min (minor).

(S_a)-9-(2-Phenyl-1H-indol-1-yl)-2-(trifluoromethyl)-9H-carbazole ((S_a)-**5e**)

Prepared according to the general procedure using *N*-(2-(phenylethynyl)phenyl)-2-(trifluoromethyl)-9H-carbazol-9-amine (**2e**; 17.1 mg, 40.0 μmol , 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5e** (9.00 mg, 21.1 μmol , 53%) as a yellow solid; mp 149.9–150.2 °C; $[\alpha]_D^{23}$ +7.1 (c 0.4, CHCl_3); R_f = 0.81 (*n*-hexane/EtOAc 15:1).

IR (neat): 3059w, 3028w, 2947w, 2909w, 1581w, 1482w, 1446m, 1322s, 1265m, 1233m, 1161m, 1122s, 1057m, 952m, 871w, 738w, 696w cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.22 (d, 3J = 8.2 Hz, 1 H, C4'H), 8.18 (d, 3J = 7.8 Hz, 1 H, C5'H), 7.80 (dt, 3J = 7.9, 4J = 0.8 Hz, 1 H, C4H), 7.60–7.56 (m, 1 H, C3'H), 7.45 (ddd, 3J = 8.3, 3J = 7.3, 4J = 1.2 Hz, 1 H, C7'H), 7.40–7.33 (m, 3 H, C2''H, C6''H, C6'), 7.32–7.30 (m, 1 H, C1'), 7.30–7.25 (m, 1 H, C5H), 7.19–7.10 (m, 4 H, C3''H, C4''H, C5''H, C6H), 7.07–7.04 (m, 1 H, C8'H), 7.01 (d, 4J = 0.8 Hz, 1 H, C3H), 6.63 (dd, 3J = 8.2, 4J = 0.8 Hz, 1 H, C7H).

^{13}C NMR (126 MHz, CDCl_3): δ = 141.6 (C8a'), 141.2 (C2), 139.9 (C9a'), 137.9 (C7a), 130.4 (C1''), 128.8 (C3'', C5''), 128.5 (C4''), 128.2 (C7'), 127.4 (C2'', C6''), 126.9 (C3a), 124.3 (C4a'), 123.7 (C6)122.4 (C5), 121.9 (C6'), 121.4 (C4), 121.3 (C5'), 121.2 (C4'), 120.7 (C4b'), 118.1 (q, $^3J_{\text{CF}}$ = 3.7 Hz, C3'), 109.54 (C7), 109.5 (C8'), 106.4 (q, $^3J_{\text{CF}}$ = 4.3 Hz, C1'), 102.8 (C3).

^{19}F NMR (376 MHz, CDCl_3): δ = –61.1 (CF_3).

HRMS (ESI): m/z [$\text{M} - \text{H}$] $^-$ calcd for $\text{C}_{27}\text{H}_{16}\text{F}_3\text{N}_2$: 425.1271; found: 425.1267.

The e.r. of 73:27 for (S_a)-**5e** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min $^{-1}$, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 4.78 (major), 5.12 min (minor).

(S_a)-2-tert-Butyl-9-(2-phenyl-1H-indol-1-yl)-9H-carbazole ((S_a)-**5f**)

Prepared according to the general procedure using 2-tert-butyl-*N*-(2-(phenylethynyl)phenyl)-9H-carbazol-9-amine (**2f**; 16.6 mg, 40.0 μmol , 1.00 equiv) followed by column chromatography (silica gel) to

give (S_a)-**5f** (13.2 mg, 31.8 μmol , 80%) as a yellow solid; mp 128.4–130.0 °C; $[\alpha]_D^{23}$ +13.7 (c 0.6, CHCl_3); R_f = 0.63 (cyclohexane/EtOAc 20:1).

IR (neat): 3058w, 2961s, 2907w, 2863w, 1608m, 1491w, 1455s, 1330m, 1245m, 1235m, 1091w, 1024w, 817w, 743s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.09–8.03 (m, 1 H, C5'H), 8.00 (d, 3J = 7.7 Hz, 1 H, C4'H), 7.75 (d, 3J = 7.9 Hz, 1 H, C4H), 7.38–7.27 (m, 5 H, C3'H, C7'H, C2''H, C6''H, C4''H), 7.25–7.19 (m, 2 H, C6'H, C5H), 7.13–7.09 (m, 2 H, C3''H, C5''H), 7.09–7.04 (m, 1 H, C6H), 6.98 (d, 4J = 1.4 Hz, 1 H, C1'H), 6.95 (d, 4J = 0.7 Hz, 1 H, C3H), 6.91 (d, 3J = 7.3 Hz, 1 H, C8'H), 6.65 (d, 3J = 8.2 Hz, 1 H, C7H), 1.26 (s, 9 H, $\text{C}(\text{CH}_3)_3$).

^{13}C NMR (126 MHz, CDCl_3): δ = 150.9 (C2'), 141.4 (C2), 140.9 (C9a'), 140.8 (C8a'), 138.0 (C7a), 130.8 (C1''), 128.6 (C3'', C5''), 128.2 (C4''), 127.4 (C2'', C6''), 126.8 (C3a), 126.2 (C7'), 123.3 (C6), 121.9 (C5), 121.8 (C4b'), 121.1 (C6'), 121.0 (C4), 120.4 (C5'), 120.1 (C4'), 119.4 (C4a'), 119.0 (C3'), 109.9 (C7), 109.0 (C8'), 105.7 (C1'), 102.2 (C3), 35.3 ($\text{C}(\text{CH}_3)_3$), 31.8 ($\text{C}(\text{CH}_3)_3$).

HRMS (ESI): m/z [$\text{M} - \text{H}$] $^-$ calcd for $\text{C}_{30}\text{H}_{25}\text{N}_2$: 413.2023; found: 413.2025.

The e.r. of 83:17 for (S_a)-**5f** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min $^{-1}$, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 4.78 (major), 4.60 min (minor).

(S_a)-2-(3,5-Dimethylphenyl)-9-(2-phenyl-1H-indol-1-yl)-9H-carbazole ((S_a)-**5g**)

Prepared according to the general procedure using 2-(3,5-dimethylphenyl)-*N*-(2-(phenylethynyl)phenyl)-9H-carbazol-9-amine (**2g**; 18.5 mg, 40.0 μmol , 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5g** (11.5 mg, 24.9 μmol , 62%) as a beige solid; mp 78.7–79.0 °C; $[\alpha]_D^{23}$ –19.8 (c 0.5, CHCl_3); R_f = 0.72 (cyclohexane/EtOAc 17:2).

IR (neat): 3058w, 3026w, 2921w, 2853w, 1603m, 1453s, 1329m, 1260m, 1232m, 1150w, 1096w, 1029m, 907s, 797s, 740s, 695m, 636s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.14 (d, 3J = 8.1 Hz, 1 H, C4'H), 8.11–8.08 (m, 1 H, C5'H), 7.76–7.73 (m, 1 H, C4H), 7.54 (dd, 3J = 8.1, 4J = 1.5 Hz, 1 H, C3'H), 7.42–7.37 (m, 2 H, C2''H, C6''H), 7.33–7.25 (m, 3 H, C1'H, C6'H, C7'H), 7.23–7.19 (m, 1 H, C5H), 7.16 (s, 2 H, C2''H, C6''H), 7.14–7.11 (m, 3 H, C3''H, C4''H, C5''H), 7.05 (ddd, 3J = 8.2, 3J = 7.2, 4J = 1.1 Hz, 1 H, C6H), 6.97 (d, 4J = 0.8 Hz, 1 H, C3H), 6.95 (s, 1 H, C4''H), 6.91–6.87 (m, 1 H, C8'H), 6.65–6.61 (m, 1 H, C7H), 2.33 (s, 6 H, 2 \times CH_3).

^{13}C NMR (126 MHz, CDCl_3): δ = 141.28 (C9a'), 141.21 (C1''), 141.18 (C2), 140.9 (C8a'), 140.6 (C2'), 138.3 (C3'', C5''), 137.9 (C7a), 130.5 (C1''), 129.0 (C4''), 128.6 (C3'', C5''), 128.2 (C4''), 127.3 (C2'', C6''), 126.7 (C3a), 126.6 (C7'), 125.4 (C2'', C6''), 123.4 (C6), 121.9 (C5), 121.5 (C4b'), 121.2 (C6'), 121.0 (C4), 120.9 (C3'), 120.78 (C4'), 120.76 (C4a'), 120.5 (C5'), 109.8 (C7), 109.0 (C8'), 107.3 (C1'), 102.1 (C3), 21.4 (CH_3).

HRMS (ESI): m/z [$\text{M} - \text{H}$] $^-$ calcd for $\text{C}_{34}\text{H}_{25}\text{N}_2$: 461.2023; found: 461.2021.

The e.r. of 80:20 for (S_a)-**5g** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min $^{-1}$, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 5.77 (major), 6.48 min (minor).

(S_a)-2-(3,5-Di-*tert*-butylphenyl)-9-(2-phenyl-1*H*-indol-1-yl)-9*H*-carbazole ((S_a)-5*h*)

Prepared according to the general procedure using 2-(3,5-di-*tert*-butylphenyl)-*N*-(2-(phenylethynyl)phenyl)-9*H*-carbazol-9-amine (**2h**); 21.9 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5h** (13.3 mg, 24.3 μmol, 61%) as a yellow solid; mp 123.3–124.5 °C; [α]_D²³ -1.7 (c 0.4, CHCl₃); R_f = 0.58 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3059w, 2961s, 2906w, 2867w, 1736w, 1596m, 1477m, 1452s, 1328w, 1233s, 1226m, 1151w, 1025w, 907m, 858w, 819w, 740s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.15–8.09 (m, 2 H, C4'*H*, C5'*H*), 7.73 (dt, ³J = 7.9, ⁴J = 0.9 Hz, 1 H, C4*H*), 7.49 (dd, ³J = 8.1, ⁴J = 1.5 Hz, 1 H, C3'*H*), 7.45–7.41 (m, 2 H, C2''*H*, C6''*H*), 7.40–7.34 (m, 2 H, C7'*H*, C4'''*H*), 7.34–7.29 (m, 1 H, C6'*H*), 7.28 (d, ⁴J = 1.8 Hz, 2 H, C2'''*H*, C6'''*H*), 7.22–7.17 (m, 1 H, C5'*H*), 7.17–7.13 (m, 3 H, C3''*H*, C4''*H*, C5''*H*), 7.10–7.07 (m, 1 H, C1'*H*), 7.07–7.02 (m, 2 H, C6*H*, C8'*H*), 6.96 (d, ³J = 0.8 Hz, 1 H, C3*H*), 6.68–6.60 (m, 1 H, C7*H*), 1.33 (s, 18 H, C(CH₃)₃).

¹³C NMR (126 MHz, CDCl₃): δ = 151.2 (C3''', C5'''), 141.8 (C2'), 141.6 (C2), 141.14 (C9a'), 141.09 (C8a'), 140.99 (C1'''), 138.2 (C7a), 130.8 (C1''), 128.8 (C3'', C5''), 128.4 (C4''), 127.5 (C2'', C6''), 126.9 (C3a), 126.7 (C7'), 123.4 (C6), 122.2 (C5), 122.1 (C2''', C6'''), 121.7 (C4a'/C4b'), 121.6 (C4'''), 121.27 (C6'), 121.26 (C4), 121.1 (C3'), 120.7 (C4'/C5'), 110.0 (C7), 109.2 (C8'), 107.8 (C1'), 102.3 (C3), 35.1 (C(CH₃)₃), 31.6 (C(CH₃)₃).

HRMS (ESI): *m/z* [M - H]⁻ calcd for C₄₀H₃₇N₂: 545.2962; found: 545.2955.

The e.r. of 81:19 for (S_a)-**5h** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 3.95 (major), 3.72 min (minor).

(S_a)-2-([1,1':3',1''-Terphenyl]-5'-yl)-9-(2-phenyl-1*H*-indol-1-yl)-9*H*-carbazole ((S_a)-5*i*)

Prepared according to the general procedure using 2-([1,1':3',1''-terphenyl]-5'-yl)-*N*-(2-(phenylethynyl)phenyl)-9*H*-carbazol-9-amine (**2i**); 23.5 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5i** (21.1 mg, 36.0 μmol, 90%) as a beige viscous solid; [α]_D²³ -6.0 (c 0.9, CHCl₃); R_f = 0.58 (cyclohexane/CH₂Cl₂ 1:1).

IR (neat): 3058w, 3035w, 2960w, 2928w, 2856w, 1891w, 1730m, 1577, 1596m, 1494m, 1453s, 1411m, 1330m, 1262m, 1230m, 1095w, 1025w, 795s, 758s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.19 (d, ³J = 8.1 Hz, 1 H, C4'*H*), 8.13 (d, ³J = 7.7 Hz, 1 H, C5'*H*), 7.75–7.71 (m, 2 H, C4*H*, C4'''*H*), 7.69 (d, ⁴J = 1.4 Hz, 2 H, C2''*H*, C6''*H*), 7.67–7.60 (m, 5 H, 2 × C10*H*, 2 × C14*H*, C3'*H*), 7.50–7.43 (m, 4 H, 2 × C11*H*, 2 × C13*H*), 7.42–7.39 (m, 2 H, C2''*H*, C6''*H*), 7.39–7.31 (m, 3 H, 2 × C12*H*, C7'*H*), 7.31–7.28 (m, 2 H, C1'*H*, C6'*H*), 7.22–7.18 (m, 1 H, C5'*H*), 7.16–7.11 (m, 3 H, C3''*H*, C4''*H*, C5''*H*), 7.09–7.02 (m, 1 H, C6*H*), 7.00–6.93 (m, 2 H, C3*H*, C8'*H*), 6.66 (d, ³J = 8.2 Hz, 1 H, C7*H*).

¹³C NMR (126 MHz, CDCl₃): δ = 142.7 (C1'''), 142.5 (C3''', C5'''), 141.28 (C2), 141.26 (C9a'), 141.23 (C15), 141.12 (C8a'), 140.4 (C2'), 138.1 (C7a), 130.7 (C1''), 128.9 (C11, C13), 128.8 (C3'', C5''), 128.4 (C4''), 127.7 (C12), 127.5 (C10, C14), 127.4 (C2'', C6''), 127.0 (C7'), 126.9 (C3a), 125.7 (C2''', C6'''), 125.4 (C4'''), 123.5 (C6), 122.1 (C5), 121.6 (C4b'), 121.4 (C6'), 121.23 (C3'), 121.20 (C4), 121.12 (C4a'), 121.09 (C4'), 120.8 (C5'), 109.9 (C7), 109.3 (C8'), 107.7 (C1'), 102.5 (C3).

HRMS (ESI): *m/z* [M - H]⁻ calcd for C₄₄H₂₉N₂: 585.2336; found: 585.2324.

The e.r. of 80:20 for (S_a)-**5i** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 96.5:3.5; 40 °C): t_R = 14.5 (major), 16.3 min (minor).

(S_a)-2-(2,6-Dimethylphenyl)-9-(2-phenyl-1*H*-indol-1-yl)-9*H*-carbazole ((S_a)-5*j*)

Prepared according to the general procedure using 2-(2,6-dimethylphenyl)-*N*-(2-(phenylethynyl)phenyl)-9*H*-carbazol-9-amine (**2j**); 18.5 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5j** (10.3 mg, 22.3 μmol, 56%) as a beige viscous solid; [α]_D²³ +6.9 (c 0.6, CHCl₃); R_f = 0.50 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3059w, 2954w, 2921w, 2853w, 1725w, 1608m, 1491w, 1454s, 1316m, 1285w, 1231m, 1153w, 1126w, 1014w, 940w, 908w, 744s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.17–8.12 (m, 2 H, C4'*H*, C5'*H*), 7.70 (d, ³J = 7.9 Hz, 1 H, C4*H*), 7.42–7.36 (m, 1 H, C7'*H*), 7.36–7.30 (m, 3 H, C6'*H*, C2''*H*, C6''*H*), 7.23–7.16 (m, 1 H, C5'*H*), 7.14–7.00 (m, 9 H, C6*H*, C3''*H*, C4''*H*, C5''*H*, C3'''*H*, C4'''*H*, C5'''*H*, C3'*H*, C8'*H*), 6.89 (s, 1 H, C3*H*), 6.78–6.69 (m, 2 H, C1'*H*, C7*H*), 1.90 (s, 3 H, C2'''-CH₃), 1.79 (s, 3 H, C6'''-CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 141.9 (C1'''), 141.1 (C2), 140.9 (C2'), 140.8 (C9a'), 139.9 (C8a'), 137.9 (C7a), 136.3 (C2''/C6'''), 136.2 (C2''/C6'''), 130.6 (C1''), 128.6 (C3'', C5''), 128.2 (C4''), 127.4 (C2'', C6''), 127.2 (C3''', C5'''), 126.75 (C7'), 126.73 (C3a), 123.4 (C6), 122.3 (C3'), 121.9 (C5), 121.7 (C4'''), 121.3 (C4), 121.2 (C6'), 120.67 (C5'), 120.63 (C4'), 120.30 (C4a'), 109.7 (C7), 109.6 (C1'), 109.2 (C8'), 102.3 (C3), 20.9 (C2'''-CH₃/C6'''-CH₃), 20.65 (C2'''-CH₃/C6'''-CH₃).

HRMS (ESI): *m/z* [M - H]⁻ calcd for C₃₄H₂₅N₂: 461.2023; found: 461.2026.

The e.r. of 71:29 for (S_a)-**5j** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 5.42 (major), 4.93 min (minor).

(S_a)-9-(2-Phenyl-1*H*-indol-1-yl)-2-(4-(trifluoromethyl)phenyl)-9*H*-carbazole ((S_a)-5*k*)

Prepared according to the general procedure using *N*-(2-(phenylethynyl)phenyl)-2-(4-(trifluoromethyl)phenyl)-9*H*-carbazol-9-amine (**2k**); 20.1 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5k** (10.1 mg, 20.1 μmol, 50%) as a yellow solid; mp 77.8–78.5 °C; [α]_D²⁴ -5.4 (c 0.5, CHCl₃); R_f = 0.52 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3060w, 2953w, 2929w, 1730w, 1613m, 1491w, 1453m, 1406w, 1322s, 1233m, 1165s, 1121s, 1069s, 1014s, 906s, 816m, 813s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.18 (d, ³J = 8.1 Hz, 1 H, C4'*H*), 8.15–8.11 (m, 1 H, C5'*H*), 7.81–7.73 (m, 1 H, C4*H*), 7.65–7.59 (m, 4 H, C2''*H*, C3''*H*, C5''*H*, C6''*H*), 7.54 (d, ³J = 8.1 Hz, 1 H, C3'*H*), 7.41–7.28 (m, 4 H, C2''*H*, C6''*H*, C6'*H*, C7'*H*), 7.24–7.20 (m, 1 H, C5'*H*), 7.20–7.17 (m, 1 H, C1'*H*), 7.16–7.10 (m, 3 H, C3''*H*, C5''*H*, C4''*H*), 7.09–7.04 (m, 1 H, C6*H*), 7.02–6.99 (m, 1 H, C8'*H*), 6.98 (s, 1 H, C3*H*), 6.63 (d, ³J = 8.2 Hz, 1 H, C7*H*).

¹³C NMR (126 MHz, CDCl₃): δ = 144.9 (C1'''), 141.26 (C9a', C2), 141.24 (C8a'), 138.8 (C2'), 138.0 (C7a), 130.6 (C1''), 128.8 (C3'', C5''), 128.4 (C4''), 127.9 (C2''', C6'''), 127.4 (C2'', C6''), 127.3 (C7'), 126.9 (C3a), 125.86–125.66 (m, C3''', C5'''), 123.6 (C6), 122.2 (C5), 121.7 (C4a'), 121.6 (C6'), 121.4 (C4b'), 121.27 (C4), 121.25 (C4'), 120.9 (C5'), 120.8 (C3'), 109.7 (C7), 109.3 (C8'), 107.6 (C1'), 102.5 (C3).

¹⁹F NMR (471 MHz, CDCl₃): δ = -62.42.

HRMS (ESI): m/z [M - H]⁻ calcd for C₃₃H₂₀F₃N₂: 501.1584; found: 501.1580.

The e.r. of 76:24 for (S_a)-**5k** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 6.03 (major), 5.78 min (minor).

(S_a)-2-(4-Fluorophenyl)-9-(2-phenyl-1H-indol-1-yl)-9H-carbazole ((S_a)-**5l**)

Prepared according to the general procedure using 2-(4-fluorophenyl)-N-(2-(phenylethynyl)phenyl)-9H-carbazol-9-amine (**2l**; 18.1 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**5l** (12.0 mg, 26.5 μmol, 66%) as a yellow viscous solid; [α]_D¹⁹ -19.8 (c 0.3, CHCl₃); R_f = 0.47 (cyclohexane/EtOAc 20:1).

IR (neat): 3059w, 2953w, 2922w, 2858w, 1892w, 1605m, 1516m, 1491m, 1453s, 1404w, 1330w, 1231s, 1159m, 1098w, 1013w, 907s, 815s, 730s, 694m, 637m cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.15 (dd, ³J = 8.1, ⁵J = 0.5 Hz, 1 H, C4'H), 8.13–8.10 (m, 1 H, C5'H), 7.75 (dt, ³J = 7.9, ⁴J = 0.9 Hz, 1 H, C4'H), 7.50–7.46 (m, 3 H, C3'H, C2''H, C6''H), 7.42–7.38 (m, 2 H, C2''H, C6''H), 7.36–7.32 (m, 1 H, C7'H), 7.30 (td, ³J = 7.4, ⁴J = 1.2 Hz, 1 H, C6'H), 7.22 (ddd, ³J = 8.0, ³J = 7.2, ⁴J = 1.0 Hz, 1 H, C5'H), 7.15–7.12 (m, 4 H, C3''H, C4''H, C5''H, C1'H), 7.09–7.03 (m, 3 H, C6'H, C3''H, C5''H), 6.99–6.95 (m, 2 H, C3'H, C8'H), 6.63 (dq, ³J = 8.2, ⁴J = 1.0 Hz, 1 H, C7'H).

¹³C NMR (126 MHz, CDCl₃): δ = 162.6 (d, ¹J_{CF} = 246.8 Hz, C4'''), 141.30 (C2), 141.25 (C9a'), 141.13 (C8a'), 139.4 (C2'), 137.9 (C7a), 137.50 (d, ⁴J_{CF} = 3.0 Hz, C1'''), 130.6 (C1''), 129.16 (d, ³J_{CF} = 8.2 Hz, C2''', C6'''), 128.8 (C4''), 128.4 (C3'', C5''), 127.4 (C2'', C6''), 126.9 (C7'), 126.8 (C3a), 123.5 (C6), 122.1 (C5), 121.5 (C4b'), 121.4 (C6'), 121.2 (C4), 121.1 (C4'), 121.0 (C5'), 120.7 (C3'), 115.71 (d, ²J_{CF} = 21.6 Hz, C3''', C5'''), 109.8 (C7), 109.2 (C8'), 107.2 (C1'), 102.4 (C3).

¹⁹F NMR (471 MHz, CDCl₃): δ = -115.67.

HRMS (ESI): m/z [M - H]⁻ calcd for C₃₂H₂₀FN₂: 451.1616; found: 451.1613.

The e.r. of 80:20 for (S_a)-**5l** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 6.75 (major), 7.10 min (minor).

(S_a)-2,3-Dimethyl-2'-(*p*-tolyl)-1,1'-biindole ((S_a)-**6a**)

Prepared according to the general procedure using 2,3-dimethyl-N-(2-(*p*-tolylethynyl)phenyl)-1H-indol-1-amine (**3a**; 14.0 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6a** (6.70 mg, 19.1 μmol, 48%) as a beige viscous solid; mp 78.7–79.0 °C; [α]_D²⁴ +1.5 (c 0.3, CHCl₃); R_f = 0.44 (cyclohexane/CH₂Cl₂ 4:1).

IR (neat): 3054w, 2953w, 2919w, 2849w, 1722w, 1503w, 1457m, 1333m, 1284m, 1186w, 1104w, 908w, 739s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 7.68 (dt, ³J = 7.9, ⁴J = 0.9 Hz, 1 H, C4H), 7.56 (d, ³J = 7.7 Hz, 1 H, C4'H), 7.20–7.15 (m, 4 H, C5H, C5'H, C2''H, C6''H), 7.14–7.05 (m, 2 H, C6H, C6'H), 7.02–6.98 (m, 2 H, C3''H, C5''H), 6.97 (dt, ³J = 7.9, ⁴J = 0.9 Hz, 1 H, C7'H), 6.85 (d, ⁴J = 0.9 Hz, 1 H, C3H), 6.64–6.59 (m, 1 H, C7H), 2.26 (s, 3 H, C4'-CH₃), 2.25 (s, 3 H, C2'-CH₃), 1.82 (s, 3 H, C3'-CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 140.8 (C2), 138.4 (C7a), 137.9 (C4''), 136.6 (C7a'), 133.1 (C2'), 129.4 (C3'', C5''), 127.7 (C1''), 127.09 (C3a'), 127.06 (C2'', C6''), 126.2 (C3a), 123.0 (C6), 122.2 (C6'), 121.6 (C5), 120.7 (C4), 120.4 (C5'), 118.3 (C4'), 109.4 (C7), 108.8 (C7'), 107.2 (C3'), 100.9 (C3), 21.2 (C4'-CH₃), 8.9 (C2'-CH₃), 8.8 (C3'-CH₃).

HRMS (ESI): m/z [M + H]⁺ calcd for C₂₅H₂₃N₂: 351.1865; found: 351.1857.

The e.r. of 66:34 for (S_a)-**6a** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 4.68 (major), 5.27 min (minor).

(S_a)-2-tert-Butyl-9-(2-(*p*-tolyl)-1H-indol-1-yl)-9H-carbazole ((S_a)-**6b**)

Prepared according to the general procedure using 2-tert-butyl-N-(2-(*p*-tolylethynyl)phenyl)-9H-carbazol-9-amine (**3b**; 17.1 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6b** (11.7 mg, 27.3 μmol, 68%) as a beige viscous solid; [α]_D¹⁹ -15.8 (c 0.4, CHCl₃); R_f = 0.50 (cyclohexane/EtOAc 21:1).

IR (neat): 3039w, 3025w, 2961m, 2664m, 1629w, 1609m, 1504m, 1454s, 1331m, 1235m, 1020w, 907w, 818m, 743s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.11–8.03 (m, 1 H, C5'H), 8.01 (d, ³J = 8.2 Hz, 1 H, C4'H), 7.73 (d, ³J = 7.9 Hz, 1 H, C4H), 7.35 (dd, ³J = 8.3, ⁴J = 1.6 Hz, 1 H, C3'H), 7.30–7.26 (m, 2 H, C6'H, C7'H), 7.25–7.22 (m, 2 H, C2''H, C6''), 7.22–7.18 (m, 1 H, C5H), 7.08–7.02 (m, 1 H, C6H), 6.99 (d, ⁴J = 1.4 Hz, 1 H, C1'H), 6.94–6.86 (m, 4 H, C3H, C8'H, C3''H, C5''H), 6.61 (d, ³J = 8.2 Hz, 1 H, C7H), 2.17 (s, 3 H, C4'-CH₃), 1.26 (s, 9 H, C(CH₃)₃).

¹³C NMR (126 MHz, CDCl₃): δ = 150.9 (C2'), 141.6 (C2), 140.9 (C9a'), 140.8 (C8'a), 138.1 (C4''), 137.9 (C7a), 129.4 (C3'', C5''), 127.9 (C1''), 127.3 (C2'', C6''), 126.9 (C3a), 126.2 (C7'), 123.1 (C6), 121.9 (C5), 121.7 (C4b'), 120.96 (C6'), 120.92 (C4), 120.3 (C5'), 120.1 (C4'), 119.3 (C4a'), 118.9 (C3'), 109.9 (C7), 109.1 (C8'), 105.7 (C1'), 101.7 (C3), 35.3 (C4'-CH₃), 31.8 (C(CH₃)₃), 21.3 (C(CH₃)₃).

HRMS (ESI): m/z [M - H]⁻ calcd for C₃₁H₂₇N₂: 427.2180; found: 427.2185.

The e.r. of 87:13 for (S_a)-**6b** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 4.33 (major), 4.53 min (minor).

(S_a)-2-tert-Butyl-9-(2-(3,5-dimethylphenyl)-1H-indol-1-yl)-9H-carbazole ((S_a)-**6c**)

Prepared according to the general procedure using 2-tert-butyl-N-(2-(3,5-dimethylphenyl)ethynyl)phenyl)-9H-carbazol-9-amine (**3c**; 17.7 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6c** (6.00 mg, 13.6 μmol, 34%) as a yellow viscous solid; [α]_D²⁴ +36.5 (c 0.3, CHCl₃); R_f = 0.60 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3057w, 2962w, 2865w, 1734w, 1606m, 1454s, 1333m, 1240m, 1166w, 1095w, 1013w, 960w, 907m, 850m, 818m, 739s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.03 (d, ³J = 7.6 Hz, 1 H, C5'H), 7.99 (d, ³J = 8.2 Hz, 1 H, C4'H), 7.74 (d, ³J = 7.8 Hz, 1 H, C4H), 7.33 (dd, ³J = 8.2, ⁴J = 1.3 Hz, 1 H, C3'H), 7.30–7.18 (m, 3 H, C5H, C6'H, C7'H), 7.07 (t, ³J = 7.6 Hz, 1 H, C6H), 7.04 (s, 1 H, C1'H), 6.93 (s, 2 H, C2''H, C6''H), 6.89 (s, 1 H, C3H), 6.85 (d, ³J = 7.8 Hz, 1 H, C8'H), 6.76–6.70 (m, 2 H, C7H, C4''H), 2.00 (s, 6 H, C3''-CH₃, C5''-CH₃), 1.28 (s, 9 H, C(CH₃)₃).

¹³C NMR (126 MHz, CDCl₃): δ = 150.6 (C2'), 142.1 (C2), 141.0 (C8a'/C9a'), 140.9 (C8a'/C9a'), 138.1 (C7a), 137.7 (C3'', C5''), 130.4 (C1''), 129.8 (C4''), 126.7 (C3a), 126.0 (C7'), 125.4 (C2'', C6''), 123.1 (C6), 121.7 (C5), 121.6 (C4b'), 120.8 (C4), 120.7 (C6'), 120.1 (C5'), 119.9 (C4'), 119.2 (C4a'), 118.7 (C3'), 109.9 (C7), 108.9 (C8'), 105.7 (C1'), 101.9 (C3), 35.1 (C(CH₃)₃), 31.6 (C(CH₃)₃), 21.0 (C3''-CH₃, C5''-CH₃).

HRMS (ESI): m/z [M - H]⁻ calcd for C₃₂H₂₉N₂: 441.2336; found: 441.2332.

The e.r. of 85:15 for (S_a)-**6c** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 5.53 (major), 4.10 min (minor).

(S_a)-9-(2-(*p*-Tolyl)-1*H*-indol-1-yl)-2-(trifluoromethyl)-9*H*-carbazole ((S_a)-6d)

Prepared according to the general procedure using *N*-(2-(*p*-tolylethynyl)phenyl)-2-(trifluoromethyl)-9*H*-carbazol-9-amine (**3d**; 17.6 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6d** (10.5 mg, 23.8 μmol, 60%) as an orange solid; mp 119.9–120.9 °C; [α]_D²² +5.0 (c 0.5, CHCl₃); R_f = 0.44 (cyclohexane/EtOAc 20:1).

IR (neat): 3059w, 3052w, 2922w, 2863w, 1598w, 1490w, 1447w, 1444w, 1323s, 1263m, 1228m, 1164m, 1119s, 1057m, 1052w, 951w, 821m, 809w, 741s, 662w cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.20 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.15 (d, ³J = 7.8 Hz, 1 H, C5'H), 7.75 (d, ³J = 7.9 Hz, 1 H, C4H), 7.55 (dd, ³J = 8.8, ⁴J = 1.6 Hz, 1 H, C3'H), 7.44–7.40 (m, 1 H, C7'H), 7.37–7.32 (m, 1 H, C6'H), 7.29 (d, ⁴J = 1.6 Hz, 1 H, C1'H), 7.25–7.18 (m, 3 H, C2''H, C6''H, C5H), 7.07 (ddd, ³J = 8.2, ³J = 7.2, ⁴J = 1.2 Hz, 1 H, C6H), 7.04–6.99 (m, 1 H, C8'H), 6.95–6.89 (m, 3 H, C3H, C3''H, C5''H), 6.58 (dd, ³J = 8.2, ³J = 1.0 Hz, 1 H, C7H), 2.19 (s, 3 H, C4''-CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 141.5 (C8'a), 141.3 (C1'''), 139.8 (C9'a), 138.3 (C4''), 137.7 (C7a), 129.4 (C3'', C5''), 128.8–128.7 (C2'), 128.1 (C7'), 127.3 (C2), 127.1 (C2'', C6''), 126.8 (C3a), 124.2 (C4'a), 123.4 (C6), 122.2 (C5), 121.7 (C6'), 121.2 (C5'), 121.1 (C4), 121.0 (C4'), 120.6 (C4'b), 118.2–117.6 (m, C3'), 109.4 (C8'), 109.3 (C7), 106.5–105.9 (m, C1'), 102.2 (C3), 21.1 (CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = -61.09.

HRMS (ESI): *m/z* [M]⁺ calcd for C₂₈H₁₉F₃N₂: 440.1495; found: 440.1486.

The e.r. of 79:21 for (S_a)-**6d** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 4.73 (major), 5.48 min (minor).

(S_a)-2-Phenyl-9-(2-(*p*-tolyl)-1*H*-indol-1-yl)-9*H*-carbazole ((S_a)-6e)

Prepared according to the general procedure using 2-phenyl-*N*-(2-(*p*-tolylethynyl)phenyl)-9*H*-carbazol-9-amine (**3e**; 17.9 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6e** (14.0 mg, 31.2 μmol, 78%) as a beige viscous solid; [α]_D²² -1.9 (c 0.7, CHCl₃); R_f = 0.48 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3052w, 3027w, 2921w, 2856w, 1730w, 1608w, 1484w, 1454s, 1316w, 1233m, 1111w, 1018w, 745s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.16 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.12 (d, ³J = 7.3 Hz, 1 H, C5'H), 7.73 (d, ³J = 7.9 Hz, 1 H, C4H), 7.59–7.50 (m, 3 H, C2''H, C6''H, C3'H), 7.38 (t, ³J = 7.6 Hz, 2 H, C3''H, C5''H), 7.36–7.27 (m, 5 H, C2''H, C6''H, C6'H, C7'H, C4''H), 7.23–7.16 (m, 2 H, C1'H, C5H), 7.04 (t, ³J = 7.7 Hz, 1 H, C6H), 6.99–6.91 (m, 4 H, C3H, C3''H, C5''H, C8'H), 6.61 (d, ³J = 8.2 Hz, 1 H, C7H), 2.19 (s, 3 H, CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 141.34 (C2), 141.26 (C1'''), 141.19 (C9a'), 141.0 (C8a'), 140.2 (C2'), 138.1 (C4''), 137.8 (C7a), 129.4 (C3'', C5''), 128.7 (C3''', C5'''), 127.5 (C2''', C6'''), 127.3 (C4'''), 127.1 (C2'', C6''), 126.8 (C3a), 126.7 (C7'), 123.1 (C6), 121.9 (C5), 121.4 (C4b'), 121.2 (C6'), 120.87 (C4a'), 120.85 (C4/C4'), 120.7 (C5'), 120.5 (C3'), 109.6 (C7), 109.1 (C8'), 107.3 (C1'), 101.7 (C3), 21.1 (CH₃).

HRMS (ESI): *m/z* [M - H]⁻ calcd for C₃₃H₂₃N₂: 447.1867; found: 447.1871.

The e.r. of 82:18 for (S_a)-**6e** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 5.23 (major), 5.45 min (minor).

(S_a)-2-Phenyl-9-(2-(*m*-tolyl)-1*H*-indol-1-yl)-9*H*-carbazole ((S_a)-6f)

Prepared according to the general procedure using 2-phenyl-*N*-(2-(*m*-tolylethynyl)phenyl)-9*H*-carbazol-9-amine (**3f**; 17.9 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6f** (13.2 mg, 29.4 μmol, 74%) as a yellow solid; mp 86.7–88.0 °C; [α]_D²⁴ -11.6 (c 0.6, CHCl₃); R_f = 0.53 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3057w, 3030w, 2961w, 2922w, 2855w, 1607m, 1484m, 1453s, 1316m, 1234m, 1149w, 1093w, 1027w, 906s, 861w, 782m, 730s, 633w cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.15 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.13–8.08 (m, 1 H, C5'H), 7.73 (d, ³J = 7.9 Hz, 1 H, C4H), 7.56–7.49 (m, 3 H, C2''H, C6''H, C3'H), 7.40–7.36 (m, 2 H, C3''H, C5''H), 7.33 (td, ³J = 7.6, ⁴J = 1.3 Hz, 1 H, C7'H), 7.31–7.26 (m, 3 H, C6'H, C2''H, C4''H), 7.22–7.17 (m, 2 H, C5H, C1'H), 7.13 (d, ³J = 7.6 Hz, 1 H, C6'H), 7.05 (ddd, ³J = 8.2, ³J = 7.2, ⁴J = 1.0 Hz, 1 H, C6H), 7.00–6.91 (m, 4 H, C3H, C8'H, C4''H, C5''H), 6.68–6.63 (m, 1 H, C7H), 2.12 (s, 3 H, CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 141.4 (C2), 141.3 (C1'''), 141.2 (C9a'), 141.1 (C8a'), 140.2 (C2'), 138.0 (C3''), 137.9 (C7a), 130.4 (C1''), 128.9 (C4''), 128.7 (C3''', C5'''), 128.4 (C5'), 128.2 (C2''), 127.5 (C6'', C2'''), 127.3 (C4'), 126.7 (C7'), 124.1 (C6''), 123.3 (C6), 121.9 (C5), 121.4 (C4b'), 121.2 (C6'), 120.96 (C4), 120.85 (C4a'), 120.81 (C4'), 120.7 (C3'), 120.5 (C5'), 109.7 (C7), 109.1 (C8'), 107.3 (C1'), 102.1 (C3), 21.3 (CH₃).

HRMS (ESI): *m/z* [M - H]⁻ calcd for C₃₃H₂₃N₂: 447.1867; found: 447.1861.

The e.r. of 80:20 for (S_a)-**6f** was determined by NP-HPLC (Chiralpak IA analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 6.05 (major), 6.67 min (minor).

(S_a)-2-Phenyl-9-(2-(*o*-tolyl)-1*H*-indol-1-yl)-9*H*-carbazole ((S_a)-6g)

Prepared according to a modified general procedure (90 h reaction time) using 2-phenyl-*N*-(2-(*o*-tolylethynyl)phenyl)-9*H*-carbazol-9-amine (**3g**; 17.9 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6g** (10.0 mg, 22.3 μmol, 56%) as a yellow viscous solid; [α]_D²² -5.7 (c 0.6, CHCl₃); R_f = 0.36 (cyclohexane/CH₂Cl₂ 3:1).

¹H NMR (500 MHz, CDCl₃): δ = 8.07 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.04 (d, ³J = 7.7 Hz, 1 H, C5'H), 7.77–7.72 (m, 1 H, C4H), 7.57–7.52 (m, 2 H, C2''H, C6''H), 7.50 (dd, ³J = 8.1, ⁴J = 1.5 Hz, 1 H, C3'H), 7.43–7.37 (m, 2 H, C3''H, C5''H), 7.36–7.26 (m, 3 H, C4''H, C6'H, C7'H), 7.25–7.23 (m, 1 H, C1'H), 7.23–7.19 (m, 2 H, C5H, C6''H), 7.11 (d, ³J = 7.6 Hz, 1 H, C3''H), 7.07 (td, ³J = 7.7, ⁴J = 1.0 Hz, 1 H, C6H), 7.05–6.99 (m, 2 H, C4''H, C8'H), 6.82 (t, ³J = 7.6 Hz, 1 H, C5''H), 6.79 (d, ⁴J = 0.8 Hz, 1 H, C3H), 6.69–6.64 (m, 1 H, C7H), 2.51 (s, 3 H, CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 141.5 (C1'''), 141.3 (C8a'), 140.1 (C2'), 139.9 (C9a'/C2), 137.4 (C2''), 136.8 (C7a), 130.5 (C3''), 130.2 (C6''), 129.8 (C1''), 128.9 (C3''', C5'''), 128.7 (C4''), 127.6 (C2''', C6'''), 127.4 (C4'''), 126.57 (C7'), 126.56 (C3a), 125.4 (C5''), 123.2 (C6), 121.8 (C5), 121.5 (C4b'), 121.2 (C6'), 121.1 (C4), 120.94 (C4a'), 120.87 (C4'), 120.7 (C3'), 120.6 (C5'), 109.8 (C7), 109.2 (C8'), 107.4 (C4'), 104.2 (C3), 20.9 (CH₃).

HRMS (ESI): *m/z* [M - H]⁻ calcd for C₃₃H₂₃N₂: 447.1867; found: 447.1864.

The e.r. of 77:23 for (S_a)-**6g** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 5.98 (major), 6.48 min (minor).

(S_a)-9-(2-(4-*tert*-Butylphenyl)-1H-indol-1-yl)-2-phenyl-9H-carbazole ((S_a)-6h)

Prepared according to the general procedure using *N*-(2-((4-*tert*-butylphenyl)ethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**3h**; 19.6 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6h** (8.40 mg, 17.1 μmol, 43%) as a beige solid; mp 212.0–214.7 °C; [α]_D²⁴ +6.4 (c 0.4, CHCl₃); R_f = 0.57 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3057w, 3035w, 2961s, 2924s, 2903s, 2860s, 1725w, 1609m, 1570w, 1454s, 1415w, 1333w, 1259s, 1097w, 1015m, 907m, 837w, 739w cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.18 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.15–8.11 (m, 1 H, C5'H), 7.72 (d, ³J = 7.9 Hz, 1 H, C4'H), 7.57 (dd, ³J = 8.1, ⁴J = 1.5 Hz, 1 H, C3'H), 7.55–7.52 (m, 2 H, C2'''H, C6'''H), 7.40–7.35 (m, 4 H, C7'H, C3'''H, C4'''H, C5'''H), 7.34–7.27 (m, 3 H, C6'H, C2''H, C6''H), 7.22 (d, ⁴J = 1.0 Hz, 1 H, C3'H), 7.20–7.13 (m, 3 H, C5'H, C3''H, C5''H), 7.04–6.99 (m, 1 H, C6'H), 6.98–6.94 (m, 2 H, C1'H, C8'H), 6.54 (d, ³J = 8.2 Hz, 1 H, C7'H), 1.18 (s, 9 H, C(CH₃)₃).

¹³C NMR (126 MHz, CDCl₃): δ = 151.3 (C4''), 141.5 (C8a'), 141.4 (C9a'), 141.31 (C2), 141.29 (C1'''), 140.4 (C2'), 137.9 (C7a), 128.9 (C2'', C6''), 127.69 (C4'''), 127.62 (C2''', C6'''), 127.4 (C1''), 126.91 (C3a), 126.90 (C3''', C5'''), 126.88 (C7'), 125.8 (C3'', C5''), 123.3 (C6), 122.0 (C5), 121.7 (C4b'), 121.4 (C6'), 121.1 (C4a'), 121.0 (C4, C4'), 120.8 (C3'), 120.7 (C5'), 109.7 (C7), 109.4 (C8'), 107.6 (C3), 101.9 (C1'), 34.7 (C(CH₃)₃), 31.2 (C(CH₃)₃).

HRMS (ESI): *m/z* [M – H]⁻ calcd for C₃₆H₂₉N₂: 489.2336; found: 489.2344.

The e.r. of 76:24 for (S_a)-**6h** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 4.48 (major), 5.22 min (minor).

(S_a)-9-(2-(3-Chlorophenyl)-1H-indol-1-yl)-2-phenyl-9H-carbazole ((S_a)-6i)

Prepared according to a modified general procedure (90 h reaction time) using 2-(3-chlorophenyl)-*N*-(2-(phenylethynyl)phenyl)-9H-carbazol-9-amine (**3i**; 18.8 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6i** (6.50 mg, 13.9 μmol, 35%) as an orange viscous solid; [α]_D²⁴ –2.6 (c 0.4, CHCl₃); R_f = 0.54 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3060w, 3026w, 2954w, 2925w, 2852w, 1725m, 1597m, 1571m, 1453s, 1430m, 1316m, 1259m, 1231m, 1096m, 1014m, 907s, 785m, 731s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.17 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.13 (d, ³J = 7.0 Hz, 1 H, C5'H), 7.75 (d, ³J = 7.9 Hz, 1 H, C4'H), 7.56 (dd, ³J = 8.1, ⁴J = 1.5 Hz, 1 H, C3'H), 7.55–7.51 (m, 2 H, C2'''H, C6'''H), 7.50 (t, ⁴J = 1.9 Hz, 1 H, C2''H), 7.42–7.27 (m, 5 H, C3'''H, C5'''H, C6'H, C8'H, C4'''H), 7.24–7.20 (m, 1 H, C5'H), 7.18 (d, ⁴J = 1.4 Hz, 1 H, C1'H), 7.17–7.14 (m, 1 H, C6''H), 7.12–7.04 (m, 2 H, C4''H, C6'H), 7.02–6.97 (m, 2 H, C3'H, C5''H), 6.94 (d, ³J = 7.4 Hz, 1 H, C8'H), 6.65 (d, ³J = 8.2 Hz, 1 H, C7'H).

¹³C NMR (126 MHz, CDCl₃): δ = 141.4 (C9a'), 141.3 (C1'''), 141.1 (C8a'), 140.6 (C2'), 139.7 (C2), 138.2 (C7a), 134.6 (C3'''), 132.3 (C1''), 130.0 (C5''), 128.9 (C3''', C5'''), 128.3 (C4''), 127.7 (C2''', C6'''), 127.6 (C2''), 127.5 (C4'''), 127.0 (C7'), 126.6 (C3a), 125.0 (C6''), 123.9 (C6), 122.3 (C5), 121.7 (C6'), 121.6 (C4b'), 121.4 (C4), 121.11 (C4a'/C3'), 121.07 (C4'), 120.8 (C5'), 109.9 (C7), 109.1 (C8'), 107.3 (C1'), 103.1 (C3).

HRMS (ESI): *m/z* [M – H]⁻ calcd for C₃₂H₂₀ClN₂: 467.1320; found: 467.1328.

The e.r. of 75:25 for (S_a)-**6i** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 5.08 (major), 5.48 min (minor).

(S_a)-2-*tert*-Butyl-9-(2-(4-fluorophenyl)-1H-indol-1-yl)-9H-carbazole ((S_a)-6j)

Prepared according to the general procedure using 2-*tert*-butyl-*N*-(2-((4-fluorophenyl)ethynyl)phenyl)-9H-carbazol-9-amine (**3j**; 17.3 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**6j** (10.6 mg, 24.5 μmol, 61%) as a white solid; mp 159.1–160.9 °C; [α]_D²⁴ +10.6 (c 0.5, CHCl₃); R_f = 0.51 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3052w, 2962w, 2926w, 2849w, 1604w, 1504m, 1454w, 1330w, 1260w, 1232m, 1157w, 1092w, 1044w, 907w, 782s, 738s, 630s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.07–8.04 (m, 1 H, C5'H), 8.01 (d, ³J = 8.1 Hz, 1 H, C4'H), 7.75 (dt, ³J = 7.9, ⁴J = 1.0 Hz, 1 H, C4'H), 7.35 (dd, ³J = 8.1, ⁴J = 1.8 Hz, 1 H, C3'H), 7.32–7.24 (m, 4 H, C7'H, C6'H, C2''H, C6''H), 7.22 (ddd, ³J = 8.0, ³J = 7.2, ⁴J = 1.0 Hz, 1 H, C5'H), 7.08 (ddd, ³J = 8.0, ³J = 7.5, ⁴J = 1.0 Hz, 1 H, C6'H), 6.95 (d, ⁴J = 1.5 Hz, 1 H, C1'H), 6.91–6.88 (m, 2 H, C3'H, C8'H), 6.82–6.75 (m, 2 H, C3''H, C5''H), 6.66 (dd, ³J = 7.9, ⁴J = 1.0 Hz, 1 H, C7'H), 1.26 (s, 9 H, 3 × CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 162.7 (d, ¹J_{CF} = 248.4 Hz, C4''), 151.0 (C2'), 140.8 (C9a'), 140.7 (C8a'), 140.4 (C1'''), 138.4 (C2), 137.9 (C7a), 129.27 (d, ³J_{CF} = 8.2 Hz, C2'', C6''), 126.7 (C3a), 126.3 (C7'), 123.5 (C6), 122.0 (C5), 121.8 (C4b'), 121.2 (C6'), 121.1 (C4), 120.5 (C5'), 120.2 (C4'), 119.4 (C4a'), 119.1 (C3'), 115.8 (d, ²J_{CF} = 21.6 Hz, C3'', C5''), 110.0 (C7), 108.9 (C3), 105.5 (C1'), 102.1 (C8'), 35.3 (C(CH₃)₃), 31.8 (C(CH₃)₃).

¹⁹F NMR (471 MHz, CDCl₃): δ = –113.15.

HRMS (ESI): *m/z* [M – H]⁻ calcd for C₃₀H₂₄FN₂: 431.1929; found: 431.1927.

The e.r. of 80:20 for (S_a)-**6j** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 20 °C): t_R = 4.25 (major), 4.42 min (minor).

(S_a)-9-(2-(2-Methoxyphenyl)-1H-indol-1-yl)-2-phenyl-9H-carbazole ((S_a)-6k)

Prepared according to the general procedure using *N*-(2-((2-methoxyphenyl)ethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**3k**; 18.6 mg, 40.0 μmol, 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/EtOAc, 6:1) to give (S_a)-**6k** (7.00 mg, 15.1 μmol, 38%) as a viscous beige solid; [α]_D²⁴ –5.9 (c 0.4, CHCl₃); R_f = 0.60 (cyclohexane/EtOAc 6:1).

IR (neat): 3058w, 2954w, 2930w, 2845w, 1730w, 1607m, 1586w, 1484w, 1454s, 1317w, 1254s, 1238w, 1180w, 1121w, 1025w, 907s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.07 (d, ³J = 8.1 Hz, 1 H, C4'H), 8.04 (d, ³J = 7.7 Hz, 1 H, C5'H), 7.75 (d, ³J = 7.9 Hz, 1 H, C4'H), 7.58–7.53 (m, 2 H, C2''H, C6''H), 7.49 (dd, ³J = 8.1, ⁴J = 1.5 Hz, 1 H, C3'H), 7.41–7.36 (m, 2 H, C3'''H, C5'''H), 7.35–7.26 (m, 4 H, C4'''H, C7'H, C6''H, C1'H), 7.25–7.18 (m, 2 H, C5'H, C6'H), 7.11 (td, ³J = 8.3, ⁴J = 1.7 Hz, 1 H, C4''H), 7.08–7.03 (m, 2 H, C6'H, C8'H), 6.89 (s, 1 H, C3'H), 6.72 (t, ³J = 7.5 Hz, 1 H, C5''H), 6.68 (d, ³J = 8.2 Hz, 1 H, C7'H), 6.65 (d, ³J = 8.3 Hz, 1 H, C3''H), 3.39 (s, 3 H, OCH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 157.6 (C2''), 141.5 (C1'''), 141.3 (C9a'), 141.2 (C8a'), 139.7 (C2'), 138.3 (C2), 137.1 (C7a), 131.7 (C6''), 130.2 (C4''), 128.8 (C3''', C5'''), 127.5 (C2''', C6'''), 127.3 (C4'''), 126.8 (C3a), 126.4 (C7'), 123.0 (C6), 121.6 (C5), 121.4 (C4b'), 121.1 (C6'), 120.9

(C4), 120.8 (C4a'), 120.6 (C3''), 120.4 (C5'/C4'), 120.32 (C5''), 120.30 (C3'), 119.8 (C1''), 110.6 (C3''), 109.72 (C7), 109.67 (C8'), 108.0 (C1'), 103.9 (C3), 55.1 (OCH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₃₃H₂₅N₂O: 465.1961; found: 465.1951.

The e.r. of 70:30 for (S_a)-**6k** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): *t_R* = 7.57 (major), 9.50 min (minor).

(S_a)-9-(2-(2-Methoxyphenyl)-1H-indol-1-yl)-2-(trifluoromethyl)-9H-carbazole ((S_a)-**6l**)

Prepared according to the general procedure using *N*-(2-((2-methoxyphenyl)ethynyl)phenyl)-2-(trifluoromethyl)-9H-carbazol-9-amine (**3l**; 18.3 mg, 40.0 μmol, 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/CH₂Cl₂ 2:1) to give (S_a)-**6l** (5.20 mg, 11.4 μmol, 29%) as a white solid; mp 167.5–170.0 °C; [α]_D²⁴ +8.1 (c 0.3, CHCl₃); *R_f* = 0.48 (cyclohexane/CH₂Cl₂, 4:1).

IR (neat): 3062w, 2961w, 2921w, 2843w, 1631w, 1608w, 1583w, 1485w, 1448m, 1415w, 1321s, 1295w, 1261m, 1235m, 1160w, 1115s, 1054m, 1020m, 951m, 876w, 820w, 738m, 723m cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.10 (d, ³*J* = 8.2 Hz, 1 H, C4'H), 8.06 (d, ³*J* = 7.8 Hz, 1 H, C5'H), 7.77 (d, ³*J* = 7.9 Hz, 1 H, C4H), 7.48 (d, ³*J* = 8.2 Hz, 1 H, C3'H), 7.42–7.35 (m, 2 H, C1'H, C7'H), 7.31–7.26 (m, 2 H, C6'H, C6''H), 7.25–7.21 (m, 1 H, C5H), 7.14–7.06 (m, 2 H, C6H, C4''H), 7.02 (d, ³*J* = 8.2 Hz, 1 H, C8'H), 6.85 (d, ⁴*J* = 0.7 Hz, 1 H, C3H), 6.72 (td, ³*J* = 7.5, ⁴*J* = 0.9 Hz, 1 H, C5''H), 6.62 (d, ³*J* = 8.2 Hz, 2 H, C3''H, C7H), 3.40 (s, 3 H, OCH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 157.5 (C2''), 141.5 (C8a'), 139.7 (C9a'), 138.3 (C2), 136.9 (C7a), 131.8 (C6''), 130.3 (C4''), 127.5 (C7'), 126.8 (C3a), 123.9 (C4a'), 123.1 (C6), 121.7 (C5), 121.3 (C6'), 121.1 (C4), 120.8 (C5'), 120.6 (C4'), 120.4 (C4b'), 120.1 (C5''), 119.3 (C1''), 117.52–117.31 (m, C3'), 110.3 (C3''), 109.8 (C8'), 109.2 (C7), 107.18 (q, ³*J*_{CF} = 4.2 Hz, C1'), 103.9 (C3), 54.8 (OCH₃).

¹⁹F NMR (471 MHz, CDCl₃): δ = –61.04.

HRMS (ESI): *m/z* [M – H][–] calcd for C₂₈H₁₈F₃N₂O: 455.1377; found: 455.1373.

The e.r. of 68:32 for (S_a)-**6l** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): *t_R* = 5.30 (major), 5.72 min (minor).

9-(2-(Mesityl)-1H-indol-1-yl)-2-phenyl-9H-carbazole (rac-**6m**)

N-(2-(Mesitylethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**3m**; 19.1 mg, 40.0 μmol, 1.00 equiv) and Pd(CH₃CN)₂Cl₂ (2.08 mg, 8.00 μmol, 1.00 equiv) were dissolved in dry EtOH (10 mL) and the resulting mixture was stirred at 80 °C for 48 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, cyclohexane/CH₂Cl₂ from 1:0 to 10:1) to give *rac*-**6m** (15.3 mg, 32.1 μmol, 80%) as a beige viscous solid; *R_f* = 0.51 (cyclohexane/CH₂Cl₂, 3:1).

IR (neat): 3055w, 3012w, 2959w, 2921w, 2860w, 1729w, 1609m, 1567w, 1484w, 1454s, 1312m, 1229m, 1150w, 1076w, 1037w, 907m, 853m, 803w, 735s, 697s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.07 (d, ³*J* = 8.1 Hz, 1 H, C4'H), 8.05–8.02 (m, 1 H, C5'H), 7.76–7.73 (m, 1 H, C4H), 7.54–7.46 (m, 3 H, C3'H, C2''H, C6''H), 7.39 (t, ³*J* = 7.7 Hz, 2 H, C3''H, C5''H), 7.32–7.26 (3 H, C4''H, C6'H, C7'H), 7.24–7.22 (m, 1 H, C1'H), 7.22–7.18 (m, 1 H, C5H), 7.05–6.97 (m, 2 H, C6H, C8'H), 6.72 (d, ³*J* = 6.7 Hz, 2 H, C3''H, C5''H), 6.67 (d, ⁴*J* = 0.8 Hz, 1 H, C3H), 6.51–6.47 (m, 1 H, C7H), 2.30 (s, 3 H, C2''-CH₃), 2.22 (s, 3 H, C6''-CH₃), 2.13 (s, 3 H, C4''-CH₃).

¹³C NMR (126 MHz, CDCl₃): δ = 141.4 (C1'''), 141.1 (C2'), 140.9 (C9a'), 139.4 (C8a'), 138.8 (C2), 138.7 (C6''), 138.6 (C2''), 138.4 (C4''), 136.3 (C7a), 128.7 (C3''', C5'''), 128.2 (C5''), 128.1 (C3''), 127.4 (C2''', C6'''), 127.2 (C4'''), 126.9 (C1''), 126.3 (C3a), 125.9 (C7'), 122.7 (C5), 121.6 (C4b'), 121.3 (C6/C6'), 121.1 (C4a'), 120.9 (C4), 120.6 (C3'), 120.5 (C4'), 120.3 (C5'), 110.1 (C8'), 109.7 (C7), 108.4 (C1'), 104.2 (C3), 21.6 (C2''-CH₃), 21.4 (C6''-CH₃), 21.0 (C4''-CH₃).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₃₅H₂₉N₂: 477.2325; found: 477.2318.

9-(2-(2,6-Dichlorophenyl)-1H-indol-1-yl)-2-phenyl-9H-carbazole (rac-**6n**)

N-(2-(2,6-Dichlorophenyl)ethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**3n**; 20.1 mg, 40.0 μmol, 1.00 equiv) and Pd(CH₃CN)₂Cl₂ (2.08 mg, 8.00 μmol, 1.00 equiv) were dissolved in dry EtOH (10 mL) and the resulting mixture was stirred at 80 °C for 48 h. The solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, cyclohexane/CH₂Cl₂ from 1:0 to 10:1) to give *rac*-**6n** (17.0 mg, 33.8 μmol, 84%) as a yellow viscous solid; *R_f* = 0.60 (cyclohexane/EtOAc, 15:2).

IR (neat): 3059w, 2954w, 2924w, 2852w, 1721w, 1607w, 1557w, 1455s, 1427s, 1316m, 1230m, 1152w, 1096w, 1014w, 907w, 867w, 823w, 784w, 734s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.09–8.06 (m, 1 H, C4'H), 8.05 (dt, ³*J* = 7.6, ⁴*J* = 0.9 Hz, 1 H, C5'H), 7.79 (dt, ³*J* = 7.9, ⁴*J* = 1.0 Hz, 1 H, C4H), 7.59–7.55 (m, 2 H, C2''H, C6''H), 7.53–7.49 (m, 2 H, C1'H, C3'H), 7.41–7.36 (m, 2 H, C3''H, C5''H), 7.33–7.27 (m, 3 H, C6'H, C7'H, C4''H), 7.25–7.18 (m, 4 H, C5H, C8'H, C3''H, C5''H), 7.11 (t, ³*J* = 8.1 Hz, 1 H, C4''H), 7.05 (td, ³*J* = 7.7, ⁴*J* = 1.0 Hz, 1 H, C6H), 6.88 (d, ⁴*J* = 0.8 Hz, 1 H, C3H), 6.50–6.43 (m, 1 H, C7H).

¹³C NMR (126 MHz, CDCl₃): δ = 141.6 (C9a'), 141.5 (C8a'), 141.3 (C1'''), 139.7 (C2'), 137.5 (C2''/C6''), 137.35 (C2''/C6''), 136.3 (C7a), 134.4 (C2), 130.9 (C4''), 129.5 (C1''), 128.8 (C3''', C5'''), 128.3 (C3''/C5''), 128.2 (C3''/C5''), 127.6 (C2''', C6'''), 127.3 (C4'''), 126.10 (C3a), 126.08 (C7'), 123.7 (C6), 121.9 (C4b'), 121.70 (C4), 121.68 (C5), 121.4 (C6''), 121.35 (C4a'), 120.9 (C3'), 120.6 (C4'), 120.3 (C5'), 111.1 (C8'), 109.9 (C7), 109.1 (C1'), 105.7 (C3).

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₃₂H₂₁Cl₂N₂: 503.1076; found: 503.1068.

(S_a)-9-(5-Fluoro-2-phenyl-1H-indol-1-yl)-2-phenyl-9H-carbazole ((S_a)-**7a**)

Prepared according to the general procedure using *N*-(4-fluoro-2-(phenylethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**4a**; 18.1 mg, 40.0 μmol, 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**7a** (11.5 mg, 25.4 μmol, 64%) as a white solid; mp 95.6–97.0 °C; [α]_D²² –16.1 (c 0.6, CHCl₃); *R_f* = 0.36 (cyclohexane/CH₂Cl₂ 3:1).

IR (neat): 3055w, 2971w, 2904w, 1606w, 1499m, 1453s, 1408w, 1316m, 1232s, 1219m, 1074s, 908w, 860w, 818w, 691s cm⁻¹.

¹H NMR (500 MHz, CDCl₃): δ = 8.15 (d, ³*J* = 8.1 Hz, 1 H, C4'H), 8.13–8.08 (m, 1 H, C5'H), 7.55 (dd, ³*J* = 8.1, ⁴*J* = 1.6 Hz, 1 H, C3'H), 7.54–7.51 (m, 2 H, C2''H, C6''H), 7.42–7.36 (m, 5 H, C3''H, C5''H, C2''H, C6''H, C4H), 7.34 (td, ³*J* = 7.7, ⁴*J* = 1.3 Hz, 1 H, C7'H), 7.32–7.28 (m, 2 H, C6'H, C4''H), 7.18 (d, ⁴*J* = 1.1 Hz, 1 H, C1'H), 7.16–7.11 (m, 3 H, C3''H, C4''H, C5''H), 6.95 (d, ³*J* = 7.7 Hz, 1 H, C8'H), 6.92 (d, ⁴*J* = 0.6 Hz, 1 H, C3H), 6.79 (td, ³*J* = 9.1, ⁴*J* = 2.4 Hz, 1 H, C6H), 6.53 (dd, ³*J* = 8.9, ⁴*J* = 4.3 Hz, 1 H, C7H).

^{13}C NMR (126 MHz, CDCl_3): δ = 159.3 (d, $^1J_{\text{CF}}$ = 236.8 Hz, C5), 142.9 (C2), 141.3 (C1'''), 141.2 (C9a'), 141.0 (C8a'), 140.5 (C2'), 134.3 (C7a), 130.3 (C1''), 128.9 (C3'', C5''), 128.8 (C2'', C6''), 128.6 (C4''), 127.6 (C2''', C6'''), 127.5 (C4'''), 127.4 (C3''', C5'''), 127.3 (C3a), 126.9 (C7'), 121.7 (C4b'), 121.5 (C6'), 121.09 (C4'), 121.06 (C4a'), 121.02 (C3'), 120.8 (C5'), 111.70 (d, $^2J_{\text{CF}}$ = 26.4 Hz, C6), 110.6 (d, $^3J_{\text{CF}}$ = 9.6 Hz, C7), 109.1 (C8'), 107.3 (C1'), 106.33 (d, $^2J_{\text{CF}}$ = 24.1 Hz, C4), 102.16 (d, $^4J_{\text{CF}}$ = 4.4 Hz, C3).

^{19}F NMR (471 MHz, CDCl_3): δ = -122.09.

HRMS (ESI): m/z [M - H]⁻ calcd for $\text{C}_{32}\text{H}_{20}\text{FN}_2$: 451.1616; found: 451.1620.

The e.r. of 80:20 for (S_a)-**7a** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 5.63 (major), 5.42 min (minor).

(S_a)-9-(5-Methyl-2-phenyl-1H-indol-1-yl)-2-phenyl-9H-carbazole ((S_a)-7b**)**

Prepared according to the general procedure using *N*-(4-methyl-(phenylethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**4b**; 17.9 mg, 40.0 μmol , 1.00 equiv) followed by column chromatography (silica gel) to give (S_a)-**7b** (13.0 mg, 29.0 μmol , 73%) as a white solid; mp 126.0–127.7 °C; $[\alpha]_D^{22}$ -23.7 (c 0.7, CHCl_3); R_f = 0.40 (cyclohexane/ CH_2Cl_2 3:1).

IR (neat): 3058w, 3023w, 2917w, 1729w, 1607m, 1454m, 1316m, 1233m, 1132w, 1074w, 1013w, 906s, 870w, 798m, 728s, 694s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.14 (dd, 3J = 8.1, 4J = 0.6 Hz, 1 H, C4'H), 8.13–8.07 (m, 1 H, C5'H), 7.58–7.50 (m, 4 H, C4H, C2'''H, C6'''H, C3'H), 7.43–7.27 (m, 7 H, C2''H, C6''H, C3'''H, C5'''H, C6'H, C7'H, C4''H), 7.22–7.18 (m, 1 H, C1'H), 7.15–7.05 (m, 3 H, C3''H, C4''H, C5''H), 6.96 (dt, 3J = 8.4, 4J = 0.8 Hz, 1 H, C8'H), 6.89 (d, 4J = 0.8 Hz, 1 H, C3H), 6.88–6.86 (m, 1 H, C6H), 6.52 (d, 3J = 8.3 Hz, 1 H, C7H), 2.44 (s, 3 H, CH₃).

^{13}C NMR (126 MHz, CDCl_3): δ = 141.41 (C9a'/C2/C1'''), 141.40 (C9a'/C2/C1'''), 141.39 (C9a'/C2/C1'''), 141.2 (C8a'), 140.4 (C2'), 136.4 (C7a), 131.5 (C5), 130.8 (C1''), 128.8 (C3''/C5''), 128.7 (C3'''/C5'''), 128.2 (C4''), 127.6 (C2'''/C6'''), 127.4 (C4'''), 127.3 (C2''/C6''), 127.1 (C3a), 126.9 (C7'), 124.9 (C6), 121.6 (C4b'), 121.3 (C6'), 121.0 (C4'/C3'), 120.9 (C4a'), 120.8 (C4), 120.7 (C5'), 109.5 (C7), 109.2 (C8'), 107.4 (C1'), 101.9 (C3), 21.6 (CH₃).

HRMS (ESI): m/z [M - H]⁻ calcd for $\text{C}_{33}\text{H}_{23}\text{N}_2$: 447.1867; found: 447.1873.

The e.r. of 80:20 for (S_a)-**7b** was determined by NP-HPLC (Chiralpak IB analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 5.13 (major), 5.37 min (minor).

(S_a)-9-(5-Chloro-2-phenyl-1H-indol-1-yl)-2-phenyl-9H-carbazole ((S_a)-7c**)**

Prepared according to the general procedure using *N*-(4-chloro-2-(phenylethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**4c**; 18.8 mg, 40.0 μmol , 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/ CH_2Cl_2 3:1) to give (S_a)-**7c** (14.0 mg, 29.9 μmol , 75%) as a beige viscous solid; $[\alpha]_D^{22}$ -41.9 (c 0.7, CHCl_3); R_f = 0.45 (cyclohexane/ CH_2Cl_2 3:1).

IR (neat): 3059w, 3037w, 1607w, 154w, 1488m, 1454s, 1412w, 1317w, 1233m, 1179w, 1063w, 908w, 864w, 795m, 755s, 695s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.15 (d, 3J = 8.1 Hz, 1 H, C4'H), 8.11 (d, 3J = 7.2 Hz, 1 H, C5'H), 7.71 (d, 4J = 1.8 Hz, 1 H, C4H), 7.56 (dd, 3J = 8.1, 4J = 1.5 Hz, 1 H, C3'H), 7.54–7.50 (m, 2 H, C2''H, C6''H), 7.41–7.36 (m, 4 H, C2''H, C6''H, C3'''H, C5'''H), 7.36–7.27 (m, 3 H, C6'H, C7'H, C4''H),

7.16 (d, 4J = 1.1 Hz, 1 H, C1'H), 7.16–7.12 (m, 3 H, C3''H, C5''H, C4''H), 7.00 (dd, 3J = 8.6, 4J = 1.8 Hz, 1 H, C6H), 6.94 (d, 3J = 7.6 Hz, 1 H, C8'H), 6.90 (d, 4J = 0.5 Hz, 1 H, C3H), 6.54 (d, 3J = 8.6 Hz, 1 H, C7H).

^{13}C NMR (126 MHz, CDCl_3): δ = 142.6 (C2), 141.3 (C1'''), 141.2 (C9a'), 140.9 (C8a'), 140.6 (C2'), 136.2 (C7a), 130.1 (C1''), 128.9 (C3'', C5''), 128.8 (C2'', C6''), 128.7 (C4''), 127.8 (C3a), 127.7 (C5), 127.6 (C2''', C6'''), 127.5 (C4'''), 127.4 (C3''', C5'''), 126.9 (C7'), 123.7 (C6), 121.7 (C4b'), 121.6 (C6'), 121.11 (C4a'), 121.08 (C4'), 121.07 (C3'), 120.8 (C5'), 120.7 (C4), 110.9 (C7), 109.1 (C8'), 107.3 (C1'), 101.7 (C3).

HRMS (ESI): m/z [M - H]⁻ calcd for $\text{C}_{32}\text{H}_{20}\text{ClN}_2$: 467.1320; found: 467.1321.

The e.r. of 80:20 for (S_a)-**7b** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 7.80 (major), 7.45 min (minor).

(S_a)-9-(5-Chloro-2-phenyl-1H-indol-1-yl)-2-(3,5-dimethylphenyl)-9H-carbazole ((S_a)-7d**)**

Prepared according to the general procedure using *N*-(4-chloro-2-(phenylethynyl)phenyl)-2-(3,5-dimethylphenyl)-9H-carbazol-9-amine (**4d**; 19.9 mg, 40.0 μmol , 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/ CH_2Cl_2 , 3:1) to give (S_a)-**7d** (13.5 mg, 27.2 μmol , 68%) as a beige viscous solid; $[\alpha]_D^{23}$ -46.3 (c 0.7, CHCl_3); R_f = 0.53 (cyclohexane/ CH_2Cl_2 3:1).

IR (neat): 3051w, 2961w, 2919w, 2842w, 1729w, 1604m, 1443s, 1326w, 1269w, 1232m, 1177w, 1102w, 1063w, 999w, 906sm, 848m, 819m, 728s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.13 (d, 3J = 8.1 Hz, 1 H, C4'H), 8.11–8.08 (m, 1 H, C5'H), 7.71 (d, 4J = 1.9 Hz, 1 H, C4H), 7.58–7.50 (m, 1 H, C3'H), 7.43–7.35 (m, 2 H, C2''H, C6''H), 7.34–7.26 (m, 2 H, C6'H, C7'H), 7.19 (s, 1 H, C1'H), 7.17–7.10 (m, 5 H, C3''H, C4''H, C5''H, C2'''H, C6'''H), 7.00 (dd, 3J = 8.7, 4J = 1.9 Hz, 1 H, C6H), 6.96 (s, 1 H, C4''H), 6.91 (s, 1 H, C3H), 6.87 (d, 3J = 7.2 Hz, 1 H, C8'H), 6.54 (3J = 8.7 Hz, 1 H, C7H), 2.34 (s, 6 H, 2 × CH₃).

^{13}C NMR (126 MHz, CDCl_3): δ = 142.5 (C2), 141.2 (C1'''), 141.0 (C9a'), 140.8 (C8a'), 138.3 (C3''', C5'''), 136.1 (C7a), 129.9 (C1''), 129.1 (C4'''), 128.7 (C3'', C5''), 128.6 (C4''), 127.7 (C5), 127.6 (C3a), 127.3 (C2'', C6''), 126.7 (C7'), 125.4 (C2''', C6'''), 123.6 (C6), 121.6 (C4b'), 121.4 (C6'), 121.1 (C3'), 120.9 (C4'), 120.8 (C4a'), 120.6 (C5'), 120.5 (C4), 110.8 (C7), 108.8 (C8'), 107.1 (C1'), 101.5 (C3), 21.4 (CH₃).

HRMS (ESI): m/z [M - H]⁻ calcd for $\text{C}_{34}\text{H}_{24}\text{ClN}_2$: 495.1634; found: 495.1635.

The e.r. of 79:21 for (S_a)-**7d** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): t_R = 6.83 (major), 5.60 min (minor).

(R_a)-9-(6-Methyl-2-phenyl-1H-indol-1-yl)-2-phenyl-9H-carbazole ((R_a)-7e**)**

Prepared according to the general procedure using *N*-(5-methyl-2-(phenylethynyl)phenyl)-2-phenyl-9H-carbazol-9-amine (**4e**; 17.9 mg, 40.0 μmol , 1.00 equiv) followed by preparative TLC (silica gel, cyclohexane/ CH_2Cl_2 3:1) to give (R_a)-**7e** (11.5 mg, 25.6 μmol , 64%) as a beige solid; mp 84.3–85.5 °C; $[\alpha]_D^{24}$ -36.6 (c 0.6, CHCl_3); R_f = 0.56 (cyclohexane/ CH_2Cl_2 3:1).

IR (neat): 3058w, 3023w, 2954w, 2920w, 2860w, 1729w, 1605m, 1468m, 1454s, 1317m, 1233s, 1075w, 1029w, 907s, 817m, 731s cm^{-1} .

^1H NMR (500 MHz, CDCl_3): δ = 8.17 (d, 3J = 8.1 Hz, 1 H, C4'H), 8.12 (d, 3J = 7.5 Hz, 1 H, C5'H), 7.62 (d, 3J = 8.0 Hz, 1 H, C4H), 7.58–7.52 (m, 3 H, C3'H, C2'''H, C6'''H), 7.42–7.34 (m, 4 H, C2''H, C6''H, C3'''H, C5'''H), 7.34–7.28 (m, 3 H, C7'H, C4''H, C6'H), 7.22 (s, 1 H, C1'H), 7.14–7.07

(m, 3 H, C3''H, C4''H, C5''H), 7.04 (d, $^3J = 8.0$ Hz, 1 H, C5H), 6.98 (d, $^3J = 7.9$ Hz, 1 H, C8'H), 6.92 (s, 1 H, C3H), 6.43 (s, 1 H, C7H), 2.25 (s, 3 H, CH₃).

¹³C NMR (126 MHz, CDCl₃): $\delta = 141.4$ (C1'''), 141.3 (C9a'), 141.1 (C8a'), 140.7 (C2), 140.4 (C2'), 138.5 (C7a), 133.7 (C6), 130.8 (C1''), 128.9 (C2'', C6''), 128.7 (C3'', C5''), 128.1 (C4''), 127.6 (C2''', C6'''), 127.4 (C4'''), 127.2 (C3''', C5'''), 126.9 (C7'), 124.6 (C3a), 123.9 (C5), 121.5 (C4b'), 121.3 (C6'), 120.99 (C4'), 120.9 (C4a'), 120.8 (C4), 120.74 (C5'), 120.68 (C3'), 109.7 (C7), 109.2 (C8'), 107.4 (C1'), 102.3 (C3), 21.8 (CH₃).

HRMS (ESI): m/z [M - H]⁻ calcd for C₃₃H₂₃N₂: 447.1867; found: 447.1861.

The e.r. of 80:20 for (R_a)-**7e** was determined by NP-HPLC (Chiralpak IG analytical column; 1.0 mL·min⁻¹, heptane/*i*PrOH 97.5:2.5; 40 °C): $t_R = 5.93$ (major), 5.17 min (minor).

Conflict of Interest

The authors declare no conflict of interest.

Funding Information

We gratefully acknowledge the Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (175746) and the National Centre of Competence in Research, Molecular Systems Engineering (NCCR MSE) (182895) for financial support. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 (H2020) research and innovation programme (grant agreement No. 101002471).

Acknowledgment

We thank E. Hamon for experimental support, Dr. A. Prescimone for X-ray crystallographic analysis, Prof. O. Baudoïn and Solvias for helpful discussions and the generous donation of ligands.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/a-1993-6899>.

References

- (1) (a) Clayden, J.; Moran, W. J.; Edwards, P. J.; Laplante, S. R. *Angew. Chem. Int. Ed.* **2009**, *48*, 6398. (b) Glunz, P. W. *Bioorg. Med. Chem. Lett.* **2018**, *28*, 53. (c) Toenjes, S. T.; Gustafson, J. L. *Future Chem.* **2018**, *10*, 409.
- (2) (a) Bringmann, G.; Gulder, T.; Gulder, T. A. M.; Breuning, M. *Chem. Rev.* **2011**, *111*, 563. (b) Wencel-Delord, J.; Panossian, A.; Leroux, F. R.; Colobert, F. *Chem. Soc. Rev.* **2015**, *44*, 3418. (c) Zilate, B.; Castrogiovanni, A.; Sparr, C. *ACS Catal.* **2018**, *8*, 2981.
- (3) Gustafson, J. L.; Lim, D.; Miller, S. J. *Science* **2010**, *328*, 1251.
- (4) Wang, J. Z.; Zhou, J.; Xu, C.; Sun, H.; Kürti, L.; Xu, Q. L. *J. Am. Chem. Soc.* **2016**, *138*, 5202.
- (5) Rokade, B. V.; Guiry, P. J. *ACS Catal.* **2018**, *8*, 624.
- (6) Sweetman, B. A.; Guiry, P. J. *Tetrahedron* **2018**, *74*, 5567.
- (7) Zhang, P.; Wang, X. M.; Xu, Q.; Guo, C. Q.; Wang, P.; Lu, C. J.; Liu, R. R. *Angew. Chem. Int. Ed.* **2021**, *60*, 21718.
- (8) Rodríguez-Salamanca, P.; Fernández, R.; Hornillos, V.; Lassaletta, J. M. *Chem. Eur. J.* **2022**, *28*, e202104442.
- (9) Di Iorio, N.; Righi, P.; Mazzanti, A.; Mancinelli, M.; Ciogli, A.; Bencivenni, G. *J. Am. Chem. Soc.* **2014**, *136*, 10250.
- (10) Hirai, M.; Terada, S.; Yoshida, H.; Ebine, K.; Hirata, T.; Kitagawa, O. *Org. Lett.* **2016**, *18*, 5700.
- (11) Bai, H. Y.; Tan, F. X.; Liu, T. Q.; Zhu, G. D.; Tian, J. M.; Ding, T. M.; Chen, Z. M.; Zhang, S. Y. *Nat. Commun.* **2019**, *10*, 3063.
- (12) Frey, J.; Malekafzali, A.; Delso, I.; Choppin, S.; Colobert, F.; Wencel-Delord, J. *Angew. Chem. Int. Ed.* **2020**, *59*, 8844.
- (13) Vaidya, S. D.; Toenjes, S. T.; Yamamoto, N.; Maddox, S. M.; Gustafson, J. L. *J. Am. Chem. Soc.* **2020**, *142*, 2198.
- (14) Chang, C.; Adams, R. *J. Am. Chem. Soc.* **1931**, *53*, 2353.
- (15) (a) Xu, Z.; Baunach, M.; Ding, L.; Hertweck, C. *Angew. Chem. Int. Ed.* **2012**, *51*, 10293. (b) Zhang, Q.; Mándi, A.; Li, S.; Chen, Y.; Zhang, W.; Tian, X.; Zhang, H.; Li, H.; Zhang, W.; Zhang, S.; Ju, J.; Kurtán, T.; Zhang, C. *Eur. J. Org. Chem.* **2012**, *2012*, 5256.
- (16) (a) Dai, J.; Dan, W.; Schneider, U.; Wang, J. *Eur. J. Med. Chem.* **2018**, *157*, 622. (b) Blair, L. M.; Sperry, J. J. *Nat. Prod.* **2013**, *76*, 794.
- (17) Liu, X. Y.; Zhang, Y. L.; Fei, X.; Liao, L. S.; Fan, J. *Chem. Eur. J.* **2019**, *25*, 4501.
- (18) Antognazza, P.; Benincori, T.; Mazzoli, S.; Sanniccolo, F.; Pilati, T. *Phosphorus, Sulfur Silicon Relat. Elem.* **1999**, *146*, 405.
- (19) Mei, G. J.; Wong, J. J.; Zheng, W.; Nangia, A. A.; Houk, K. N.; Lu, Y. *Chem* **2021**, *7*, 2743.
- (20) Lin, W.; Zhao, Q.; Li, Y.; Pan, M.; Yang, C.; Yang, G. H.; Li, X. *Chem. Sci.* **2022**, *13*, 141.
- (21) Pan, M.; Shao, Y. B.; Zhao, Q.; Li, X. *Org. Lett.* **2022**, *24*, 374.
- (22) (a) Xu, Q.; Zhang, H.; Ge, F. B.; Wang, X. M.; Zhang, P.; Lu, C. J.; Liu, R. R. *Org. Lett.* **2022**, *24*, 3138. (b) Wang, X. M.; Zhang, P.; Xu, Q.; Guo, C. Q.; Zhang, D. B.; Lu, C. J.; Liu, R. R. *J. Am. Chem. Soc.* **2021**, *143*, 15005.
- (23) (a) Gao, Y.; Wang, L. Y.; Zhang, T.; Yang, B. M.; Zhao, Y. *Angew. Chem. Int. Ed.* **2022**, *61*, e202200371. (b) Chen, K. W.; Chen, Z. H.; Yang, S.; Wu, S. F.; Zhang, Y. C.; Shi, F. *Angew. Chem. Int. Ed.* **2022**, *61*, e202116829.
- (24) (a) Portolani, C.; Centonze, G.; Luciani, S.; Pellegrini, A.; Righi, P.; Mazzanti, A.; Ciogli, A.; Sorato, A.; Bencivenni, G. *Angew. Chem. Int. Ed.* **2022**, *61*, e202209895. (b) Zhang, P.; Wang, X.-M.; Feng, J.; Lu, C.-J.; Li, Y.; Liu, R. R. *Angew. Chem. Int. Ed.* **2022**, *61*, e202212101.
- (25) (a) Ototake, N.; Morimoto, Y.; Mokuya, A.; Fukaya, H.; Shida, Y.; Kitagawa, O. *Chem. Eur. J.* **2010**, *16*, 6752. (b) Morimoto, Y.; Shimizu, S.; Mokuya, A.; Ototake, N.; Saito, A.; Kitagawa, O. *Tetrahedron* **2016**, *72*, 5221.
- (26) (a) Alsabeh, P. G.; Lundgren, R. J.; Longobardi, L. E.; Stradiotto, M. *Chem. Commun.* **2011**, *47*, 6936. (b) Halland, N.; Nazare, M.; Alonso, J.; R'Kyek, O.; Lindenschmidt, A. *Chem. Commun.* **2011**, *47*, 1042.